CD8 binding agents and uses thereof
By developing CD8 binding agents with high affinity VHH domains, the problem of dynamic monitoring of CD8+ cells in vivo is solved, and cell detection with high sensitivity and linear correlation is achieved, which is suitable for cancer diagnosis and treatment response prediction and progress monitoring.
Patent Information
- Application Number
- CN202080076879.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-04
- Filing Date
- 2020-09-03
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-09-03
AI Technical Summary
Existing methods are difficult to effectively monitor the number and time distribution changes of CD8+ T cells in vivo, and traditional radiolabeling methods are limited by half-life and cell division to cause probe dilution, which cannot provide dynamic CD8+ cell information in vivo.
A CD8 binding agent containing the VHH domain of heavy chain antibodies has been developed, which has high affinity and specifically binds to CD8, and does not stimulate or inhibit CD8+ T cell activation, and can detect CD8+ cells with high sensitivity and linear correlation, suitable for short time Repeat imaging within.
It realizes high sensitivity detection and dynamic monitoring of CD8+ cells, providing more accurate information on CD8+ cells in vivo, suitable for cancer diagnosis and treatment response prediction and progress monitoring.
Smart Images

Figure CN114616250B_ABST
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims priority to U.S. Provisional Application No. 62 / 895,865, filed on September 4, 2019, the contents of which are incorporated herein by reference in their entirety.
[0003] Submission of sequence listings on ASCII text files
[0004] The following content submitted on an ASCII text file is incorporated herein by reference in its entirety: Computer Readable Form (CRF) of a Sequence Listing (File Name: 146392049240SEQLIST.txt, Date of Recording: August 19, 2020, Size: 14KB). Technical Field
[0005] The present application relates to CD8 binding agents based on anti-CD8 VHH domains and the use of such CD8 binding agents for in vivo targeting of CD8 + Methods for T-cell imaging. Background Art
[0006] Characterization of the number, type, and spatial distribution of immune cells in tumor tissue can provide critical information regarding cancer diagnosis, prognosis, therapy selection, and response to therapy. + Cytotoxic lymphocytes have been consistently reported to have diagnostic and prognostic significance in various cancers. + Cell-based methods require isolation of cells from peripheral blood or tissue of interest. This sampling method is prone to error and does not provide information reflecting in vivo CD8 + Dynamic information on cell number, localization, and motility. An exemplary non-invasive method for detecting immune cells in vivo is positron emission tomography (PET) using radiolabeled tracers. However, the use of such tracers is limited by the half-life of the radioisotope and cell division, which results in dilution of the probe in vivo. Therefore, there remains a need in the art for monitoring CD8 + Methods and reagents for changes in the number and temporal distribution of cells. Summary of the invention
[0007] Provided herein are CD8-binding agents comprising a variable domain of a heavy chain of a heavy chain antibody (VHH domain), wherein the CD8-binding agent has a K of about 1 nM or less. D Specifically binds to human CD8. In some embodiments, the CD8 binding agent has a K of about 500 pM or less, about 250 pM or less, or about 100 pM or less. DSpecifically binds to human CD8. In some embodiments, the CD8 binding agent has a K of about 132 pM or about 50 pM. D Specifically binds to human CD8. In some embodiments, the CD8 binding agent has a k of about 0.002 / s or less or about 0.001 / s or less. off Binds to human CD8. In some embodiments, the CD8 binding agent binds to human CD8 at a k of about 0.0018 / s or about 0.00085 / s. off Binds to human CD8. In some embodiments, the CD8 binding agent has a K of about 1 nM or less. D In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 with a K of about 500 pM or less, about 250 pM or less, or about 150 pM or less. D Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent has a K of about 344 pM or about 137 pM. D Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 with a k of about 0.004 / s or less or about 0.002 / s or less. off Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 at a k of about 0.0037 / s or about 0.0019 / s. off Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent has a CD8-binding half-life of at least about 30 minutes, such as at least about 1 hour, 2 hours, or longer (e.g., in an in vitro binding assay). In some embodiments, the CD8 binding agent has a K of about 1 nM or less. D Specifically binds to rhesus CD8. In some embodiments, the CD8 binding agent does not bind to mouse or rat CD8.
[0008] In some embodiments according to (or as applied to) any of the above embodiments, the CD8 binding agent does not stimulate or inhibit CD8 + In some embodiments, the CD8 binding agent does not induce CD8 + T cell proliferation. In some embodiments, the CD8 binding agent does not bind to CD4 + T cells.
[0009] In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain is a camelid VHH, such as an alpaca VHH. In some embodiments, the VHH domain is chimeric. In some embodiments, the VHH is humanized. In some embodiments, the VHH is affinity matured.
[0010] In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain specifically binds a human CD8α epitope comprising Arg25, Lys42, Gln44, Val45, Leu46, Leu47, Ser48, Pro50, Thr51, Ser52, Gln75, Arg93, Leu94, Gly95, Asp96, and Thr97, wherein the amino acid numbering is according to SEQ ID NO: 13. In some embodiments, the amino acid residues in the human CD8α epitope are within about 4.5 Å from one or more amino acid residues of the VHH domain in a crystal structure of a CD8-binding agent or VHH domain bound to human CD8α.
[0011] In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 6 or 7; a CDR2 comprising the amino acid sequence of SEQ ID NO: 8 or 9; and a CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 10-12.
[0012] In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12.
[0013] In some embodiments according to (or as applied to) any of the above embodiments, wherein the VHH domain comprises L49A, wherein the numbering is according to Kabat numbering. In some embodiments, the CD8 binding agent can be purified using Protein A affinity chromatography.
[0014] In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises one or more amino acid modifications selected from a V89T substitution, a T110Q substitution, a S112Q substitution, and an addition of A at position 114 (hereinafter "A114 addition"), wherein the numbering is according to Kabat numbering. In some embodiments, the VHH domain comprises a V89T substitution, a T110Q substitution, a S112Q substitution, and an A114 addition, wherein the numbering is according to Kabat numbering. In some embodiments, the CD8-binding agent does not bind to a pre-existing anti-VHH antibody in a subject receiving the CD8-binding agent.
[0015] In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments according to (or as applied to) any of the above embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 4.
[0016] Also provided herein is an isolated nucleic acid encoding a CD8 binding agent according to (or as applied to) any of the above embodiments. In some embodiments, an expression vector is provided, comprising a nucleic acid according to (or as applied to) any of the above embodiments. In some embodiments, a host cell comprising a nucleic acid or an expression vector according to (or as applied to) any of the above embodiments is provided. In some embodiments, the host cell is a eukaryotic cell, such as a mammalian cell, such as a CHO cell or an Expi293 cell. In some embodiments, the host cell is a prokaryotic cell, such as an E. coli cell.
[0017] Further provided herein is a method of preparing a CD8 binding agent according to (or as applied to) any of the above embodiments, the method comprising: a) culturing a host cell according to (or as applied to) any of the above embodiments under conditions wherein the agent is produced; and b) recovering the CD8 binding agent produced by the host cell.
[0018] In some embodiments according to (or as applied to) any of the above embodiments, the CD8 binding agent comprises a label. A CD8 binding agent comprising a label is referred to herein as a "labeled CD8 binding agent".
[0019] In some embodiments, a method of preparing a labeled CD8-binding agent is provided, comprising conjugating a chelating moiety to the VHH domain of a CD8-binding agent according to (or as applied to) any of the above embodiments to provide a conjugate, and mixing the conjugate with a 18 F to provide a labeled CD8 binding agent, wherein the chelating moiety is a compound of formula (I):
[0020] .
[0021] In some embodiments, the conjugate is contacted with the aluminum fluoride complex in the presence of one or more antioxidant compounds, such as methionine and / or N-acetyl-tryptophan.
[0022] Provided herein are labeled CD8 binding agents comprising an anti-CD8 VHH domain according to (or as applied to) any of the above embodiments conjugated to a label. In some embodiments, the label is a fluorescent dye, a radionuclide, or an enzyme. In some embodiments according to (or as applied to) any of the above embodiments, the label is a radionuclide. In some embodiments, the radionuclide is 18 F. 89 Zr, 99m Tc, 67 Ga, 68 Ga, 64 Cu, 52 Mn, 111 In or 124 I. In some embodiments, the VHH domain is conjugated to the label via a chelating moiety. In some embodiments, the chelating moiety is covalently linked to the VHH domain via a lysine residue. In some embodiments, the label forms a complex with the metal, wherein the complex is chelated by the chelating moiety. In some embodiments, the label is 18 F and the metal is aluminum. In some embodiments, the chelating moiety is a compound of formula (I).
[0023] Provided herein are labeled CD8 binding agents comprising an anti-CD8 VHH domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11, wherein the VHH domain is bound to a radionuclide (e.g., 18 F) conjugation. In some embodiments, the chelating moiety is a compound of formula (I), and the radionuclide is complexed with aluminum 18 F. In some embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 3.
[0024] Provided herein are labeled CD8 binding agents comprising an anti-CD8 VHH domain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12, wherein the VHH domain is bound to a radionuclide (e.g., 18 F) conjugation. In some embodiments, the chelating moiety is a compound of formula (I), and the radionuclide is complexed with aluminum 18 F. In some embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 4.
[0025] Also provided herein is a pharmaceutical composition comprising a CD8 binding agent (including a labeled CD8 binding agent) according to (or as applied to) any of the above embodiments and a pharmaceutically acceptable carrier.
[0026] Further provided herein is the use of a CD8 binding agent (including a labeled CD8 binding agent) according to (or as applied to) any of the above embodiments for treating or diagnosing a disease or condition in a subject, and the use of a CD8 binding agent (including a labeled CD8 binding agent) according to (or as applied to) any of the above embodiments in the preparation of a medicament for treating or diagnosing a disease or condition in a subject.
[0027] Further provided herein is a pharmaceutical preparation comprising a CD8 binding agent (including a labeled CD8 binding agent) according to (or as applied to) any of the above embodiments and one or more antioxidant compounds. In some embodiments, the one or more antioxidant compounds are methionine and / or N-acetyltryptophan. In some embodiments, the pharmaceutical preparation comprises methionine and N-acetyltryptophan. In some embodiments, the pharmaceutical preparation further comprises histidine and sucrose.
[0028] This article provides a method for detecting CD8 + A method for treating a cell, the method comprising: a) administering to a subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments; and b) detecting the labeled CD8 binding agent and CD8 in the subject. + cells, wherein detection of said binding indicates the presence of CD8 + In some embodiments, the labeled CD8 binding agent is detected by binding to CD8 in the subject. + The binding of cells includes CD8 + In some embodiments, the CD8 +Imaging the cells includes performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject. In some embodiments, CD8 + The cells are CD8 + In some embodiments, CD8 + The cell is a CD8+ tumor cell. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes or less) after administration. In some embodiments, the method is repeated once or more, for example, about 1 to 4 times per year. In some embodiments, the method is repeated about 1 day after pre-administration of the CD8 binding agent. In some embodiments, the method is repeated for more than 1 year. In some embodiments, the method has a sensitivity of about 1 nM to about 30 nM. In some embodiments, the subject is a human or non-human primate. In some embodiments, the subject is a cynomolgus monkey or a rhesus monkey. In some embodiments, the subject is a human. In some embodiments, the subject suffers from cancer. In some embodiments, the subject suffers from an autoimmune disease or condition, transplant rejection, or graft-versus-host disease.
[0029] Provided herein is a method for predicting the responsiveness of a subject having cancer to an immunotherapeutic agent, a cell therapy, or a cancer vaccine, the method comprising: a) administering to the subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments; and b) detecting the labeled CD8 binding agent and CD8 in tumor tissue in the subject. + T cells, wherein the detection of said binding indicates that the subject is likely to respond to the immunotherapeutic agent, cell therapy or cancer vaccine. In some embodiments, the labeled CD8 binding agent is detected to bind to the CD8 + The binding of cells includes CD8 + In some embodiments, the CD8 +Imaging the cells comprises performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject. In some embodiments, the method further comprises the following steps: (c) administering a therapeutically effective amount of an immunotherapeutic agent, a cell therapy, or a cancer vaccine to a subject in which binding has been detected. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes, or less) after administration. In some embodiments, the method is repeated one or more times, for example, about 1 to 4 times per year. In some embodiments, the method is repeated at least 1 day after the pre-administration of a CD8 binding agent. In some embodiments, the method is repeated for more than 1 year.
[0030] Also provided herein is a method of monitoring disease progression in a subject having cancer, the method comprising: a) administering to the subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments, and b) detecting the labeled CD8 binding agent and CD8 in tumor tissue in the subject at a first time point and a second time point. + In some embodiments, the binding of the labeled CD8 binding agent to the CD8 in the subject is detected. + The binding of cells includes CD8 + In some embodiments, the CD8 + Imaging the cells comprises performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject. In some embodiments, the method further comprises the steps of: (c) administering to the subject a therapeutically effective amount of an immunotherapeutic agent, a cell therapy, or a cancer vaccine, wherein at the second time point, CD8 + The level of T cells was higher than that of CD8 T cells in tumor tissue at the first time point. + Levels of T cells. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes or less) after administration. In some embodiments, the method is repeated one or more times, for example, about 1 to 4 times per year. In some embodiments, the method is repeated at least 1 day after the pre-administration of the CD8 binding agent. In some embodiments, the subject is monitored for more than 1 year.
[0031] Provided herein are methods for monitoring treatment progress in a subject having cancer who has been or is receiving an immunotherapeutic agent, a cell therapy, or a cancer vaccine, the method comprising: i) administering to the subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments together with the immunotherapeutic agent, the cell therapy, or the cancer vaccine, and ii) detecting the labeled CD8 binding agent and CD8 in tumor tissue at a first time point and a second time point. + In some embodiments, the binding of the labeled CD8 binding agent to the CD8 in the subject is detected. + The binding of cells includes CD8 + In some embodiments, the CD8 + Imaging the cells includes performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject. In some embodiments, the labeled CD8 binder is administered before the immunotherapeutic, cell therapy, or cancer vaccine, wherein the first time point is after the administration of the labeled CD8 binder and before the administration of the immunotherapeutic, cell therapy, or cancer vaccine, and wherein the second time point is after the administration of the immunotherapeutic, cell therapy, or cancer vaccine. In some embodiments, the immunotherapeutic, cell therapy, or cancer vaccine is administered before the labeled CD8 binder, wherein the first time point is after the administration of the immunotherapeutic, cell therapy, or cancer vaccine and after the administration of the labeled CD8 binder, and wherein the second time point is after the first time point. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes, or less) after administration. In some embodiments, the method is repeated one or more times, for example, about 1 to 4 times per year. In some embodiments, the method is repeated at least 1 day after the prior administration of the CD8 binding agent. In some embodiments, the subject is monitored for more than 1 year.
[0032] In some embodiments according to (or as applied to) any of the above prediction methods or monitoring methods, an immunotherapeutic is administered to a subject. In some embodiments, the immunotherapeutic is an anti-PDL1 antibody, an anti-PD1 antibody, an anti-TIGIT antibody, a TIGIT antagonist, an anti-CSF-1R antibody, an anti-CSF-1R antagonist, an anti-CEA antibody, an anti-CEA antagonist, an anti-CTLA4 antibody, a CTLA4 antagonist, an anti-OX40 antibody, or an OX40 agonist. In some embodiments, the immunotherapeutic is an anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is administered in combination with one or more therapeutic agents. In some embodiments, the one or more therapeutic agents are TARCEVA ®(erlotinib), ZELBORAF ® (vemurafenib), GAZYVA ® (obinutuzumab), AVASTIN ® (bevacizumab), COTELLIC ® (cobimetinib), ZELBORAF ® (Vemurafenib) and COTELLIC ® (cobimetinib), ALECENSA ® (alectinib), KADCYLA ® (ado-trastuzumab emtansine), HERCEPTIN ® (trastuzumab), PERJETA ® (pertuzumab), polatuzumab, INF-α, anti-CD40 agent, anti-OX40 antibody, OX40 agonist, anti-CSF-1R antibody, anti-CEA antibody, IDO inhibitor or anti-TIGIT antibody. In some embodiments, the immunotherapeutic agent is a cytokine. In some embodiments, the cytokine is IL2, artificially modified IL2, IL15 or artificially modified IL15. In some embodiments, the immunotherapeutic agent is a bispecific antigen binding molecule that specifically binds to CD3. In some embodiments, the bispecific antigen binding molecule is an antibody or an antigen binding fragment thereof. In some embodiments, the immunotherapeutic agent is a bispecific antigen binding molecule that specifically binds to CD16. In some embodiments, the bispecific antigen binding molecule is an antibody or an antigen binding fragment thereof. In some embodiments, the bispecific antigen binding molecule specifically binds to CD16A. In some embodiments, the immunotherapeutic agent is a dendritic cell modulator, such as a dendritic cell activator or a dendritic cell growth factor.
[0033] In some embodiments according to (or as applied to) any of the above predicting methods or monitoring methods, a cancer vaccine is administered to the subject. In some embodiments, the cancer vaccine is a personalized cancer vaccine (PCV).
[0034] In some embodiments according to (or as applied to) any of the above prediction methods or monitoring methods, a cell therapy is administered to a subject. In some embodiments, the cell therapy is CAR-T. In some embodiments, the cell therapy is a neoantigen-specific T cell.
[0035] Provided herein are methods for predicting responsiveness of a subject suffering from an autoimmune disease or condition, transplant rejection, or graft-versus-host disease to an immunotherapeutic agent, the method comprising: a) administering to the subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments; and b) detecting the labeled CD8 binding agent and CD8 in diseased tissue in the subject. + T cells, wherein the detection of said binding indicates that the subject is likely to respond to the immunotherapeutic agent. In some embodiments, the labeled CD8 binding agent is detected to bind to CD8 in the subject. + The binding of cells includes CD8 + In some embodiments, the CD8 + Imaging the cells comprises performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject. In some embodiments, the method further comprises the following steps: (c) administering a therapeutically effective amount of an immunotherapeutic agent to a subject in which binding has been detected. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes or less) after administration. In some embodiments, the method is repeated one or more times, for example, about 1 to 4 times per year. In some embodiments, the method is repeated at least 1 day after the pre-administration of the CD8 binding agent. In some embodiments, the method is repeated for more than 1 year.
[0036] Also provided herein is a method of monitoring disease progression in a subject suffering from an autoimmune disease or condition, transplant rejection, or graft-versus-host disease, the method comprising: a) administering to the subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments, and b) detecting the labeled CD8 binding agent and CD8 in a diseased tissue in the subject at a first time point and a second time point. + Combination of T cells, including CD8 from the first time point and the second time point + An increase in T cells indicates that an autoimmune disease or condition, transplant rejection, or graft-versus-host disease has progressed. In some embodiments, the detection of a labeled CD8 binding agent and CD8 in a subject + The binding of cells includes CD8 + In some embodiments, the CD8 +Imaging the cells comprises performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject. In some embodiments, the method further comprises the steps of: (c) administering to the subject a therapeutically effective amount of an immunotherapeutic agent, wherein at the second time point, the CD8 + T cell levels were lower than those in the diseased tissue at the first time point, CD8 + T cell levels. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes or less) after administration. In some embodiments, the method is repeated one or more times, for example, about 1 to 4 times per year. In some embodiments, the method is repeated at least 1 day after the pre-administration of the CD8 binding agent. In some embodiments, the subject is monitored for more than 1 year.
[0037] Provided herein are methods for monitoring the progress of treatment in a subject having an autoimmune disease or condition, transplant rejection, or graft-versus-host disease, the subject having been or being treated with an immunotherapeutic agent, the method comprising: i) administering to the subject a labeled CD8 binding agent according to (or as applied to) any of the above embodiments together with the immunotherapeutic agent, and ii) detecting the labeled CD8 binding agent binding to CD8 in diseased tissue at a first time point and a second time point; + In some embodiments, the binding of the labeled CD8 binding agent to the CD8 in the subject is detected. + The binding of cells includes CD8 + In some embodiments, the CD8 +Imaging the cells includes performing a positron emission tomography (PET) scan or a positron emission tomography / computerized tomography (PET / CT) scan on the subject. In some embodiments, the labeled CD8 binder is administered before the immunotherapeutic, wherein the first time point is after the administration of the labeled CD8 binder and before the administration of the immunotherapeutic, and wherein the second time point is after the administration of the immunotherapeutic. In some embodiments, the immunotherapeutic is administered before the labeled CD8 binder, wherein the first time point is after the administration of the immunotherapeutic and after the administration of the labeled CD8 binder, and wherein the second time point is after the first time point. In some embodiments, the detection is performed within about 1 day or less (e.g., about 6 hours, 4 hours, 2 hours, 90 minutes, 1 hour, 30 minutes or less) after administration. In some embodiments, the method is repeated once or more, for example, about 1 to 4 times per year. In some embodiments, the method is repeated at least 1 day after the pre-administration of the CD8 binder. In some embodiments, the subject is monitored for more than 1 year.
[0038] Provided herein is a method for identifying gut microbial strains associated with responsiveness to treatment with an immunotherapeutic agent, the method comprising: a) obtaining a gut microbiome sample from a population of subjects having cancer, the population comprising subjects that respond to treatment with the immunotherapeutic agent and subjects that do not respond to treatment with the immunotherapeutic agent; b) analyzing the gut microbiome samples of the subjects that respond to the treatment and the gut microbiome samples of the subjects that do not respond to the treatment; and c) identifying gut microbial strains associated with the subjects that respond to the treatment; wherein responsiveness is determined by detecting a CD8 binding agent labeled according to (or as applied to) any of the above embodiments and CD8 in tumor tissue in the subject. + In some embodiments, the method further comprises preparing a microbiome-based medicament comprising an intestinal microbial strain associated with responsiveness to an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is an anti-PD-1 antibody. In some embodiments, the immunotherapeutic agent is an anti-PD-L1 antibody, such as atezolizumab.
[0039] Further provided herein are kits and articles of manufacture comprising a CD8 binding agent, such as a labeled CD8 binding agent, according to (or as applied to) any of the above embodiments. In some embodiments, the kit or article of manufacture comprises instructions for using the CD8 binding agent according to any of the above methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1An alignment of the amino acid sequences of exemplary anti-CD8 VHH domains is provided, including alpaca VHH wt2C8 (SEQ ID NO: 1), humanized VHHs hu2C8v130 (SEQ ID NO: 2), hu2C8v142 (SEQ ID NO: 3), and hu2C8v144 (SEQ ID NO: 4), and a non-binding control 2C8v145 (SEQ ID NO: 5).
[0041] Figure 2 An alignment of the amino acid sequences of human CD8a (SEQ ID NO: 13), cynomolgus CD8a (SEQ ID NO: 14), and rhesus CD8a (SEQ ID NO: 15) is provided.
[0042] Figure 3 Shown are the results of experiments performed to assess CD8+ cell-specific binding of VHH-Fc variants compared to OKT8-Fc.
[0043] Figure 4 Exemplary staining results of whole blood cell samples from healthy volunteers binding to 2C8 VHH are shown. OKT8 is an anti-CD8 IgG that served as a positive control. 3E8 VHH is a non-binding negative control.
[0044] Figure 5 Schematic representation of the crystal structure of 2C8 VHH is shown. The structure on the left shows 2C8 VHH (light grey) bound to a CD8α / 8α homodimer (black, epitope highlighted in white, dimer reconstructed via crystallographic symmetry operators). The structure on the right shows the superposition of the 2C8 VHH:CD8α / 8α complex (same colour as the left image) on the published structure of the MHC class I complex with CD8α / β heterodimer (PDB ID: 3DMM, MHC I shown in light grey and CD8β shown in medium grey).
[0045] Figure 6 Shown are the results of experiments performed to assess the binding of wild-type 2C8 and 2C8.v144 VHHs to pre-existing anti-VHH antibodies in blood samples from 96 healthy donors.
[0046] Fig. 7A Provided for evaluation of CD8 + Results of experiments performed on T cell proliferation.
[0047] Figure 7BA kit is provided for evaluating CD8 T cells stimulated by anti-CD3 and anti-CD28 in the presence of 2C8v130, Lys2 VHH (non-binding control), or PBS (vehicle). + Results of experiments performed on T cell protease release responses.
[0048] Figure 7C Provided for evaluation of CD8 after SEB stimulation in the presence of 2C8v130, Lys2 VHH (non-binding control), or PBS (vehicle). + Results of experiments performed on T cell proliferation.
[0049] Fig.7D Provides a method for evaluating CD8 + Results of experiments performed on T cell proliferation.
[0050] Fig. 7E Provided for the assessment of CD8 + Results of experiments performed on T cell proliferation.
[0051] Fig. 8A Provided for evaluation of CD8 + Results of T cell proliferation experiments performed in which 10% FBS was used as culture medium.
[0052] Figure 8B Provided for evaluation of CD8 + Results of experiments performed on T cell proliferation in which 10% autologous donor plasma was used as culture medium.
[0053] Figure 8C Provided for evaluation of CD8 after SEB stimulation in the presence of 2C8v130, Lys2 VHH (non-binding control), or PBS (vehicle). + Results of T cell proliferation experiments performed in which 10% FBS was used as culture medium.
[0054] Fig.8D Provided for evaluation of CD8 after SEB stimulation in the presence of 2C8v130, Lys2 VHH (non-binding control), or PBS (vehicle). +Results of experiments performed on T cell proliferation in which 10% autologous donor plasma was used as culture medium.
[0055] Fig. 9 Shown in order to evaluate the 18 F— Results of experiments conducted to investigate the CD8 imaging ability of anti-CD8 VHH in chimeric HPBALL / Daudi tumor xenograft mice.
[0056] Fig.10 TALL1 tumor xenografted mice were injected 89 Zr-OA mAb control or 89 Zr-huOKT8.v1-OA (left) (day 0) and day 5 (i.e. day 6) after injection 18 F - control VHH or 18 F- PET MIP 90 min after anti-CD8 VHH (right).
[0057] Fig.11 Shows the injection 18 F - anti-CD8 VHH (top) or 18 F - PET MIP images of rhesus monkeys one hour after control VHH (bottom). DETAILED DESCRIPTION
[0058] Provided herein are CD8-binding agents (including anti-CD8 antibodies or antigen-binding fragments thereof) comprising a VHH domain, wherein the CD8-binding agent specifically binds to human CD8 with high affinity but does not stimulate or inhibit CD8 + T cells or induced CD8 + T cell proliferation. The CD8 binder can bind with high affinity to CD8 in non-human primates such as rhesus monkeys and cynomolgus monkeys. Compared with the CD8 binder based on traditional 4-chain antibodies, the CD8 binder described herein has higher permeability and shorter serum half-life. Therefore, the CD8 binder described herein is suitable for detecting CD8 within a short time range (e.g., within 1 day, such as 1 hour) after administration. + Cells (e.g., CD8 + T cells), thereby allowing same-day readout, repeated imaging, and multiplexed imaging in combination with other biomarkers. In addition, the CD8 binders described herein show high sensitivity to CD8, linear correlation with CD8 levels over a large dynamic range, high accuracy due to reduced sensitivity to extraneous factors such as permeability, and high image quality as reflected by high tumor to blood ratios in mouse xenograft models.
[0059] This article provides an in vivo assay for CD8 +Methods of using the CD8 binding agents herein in methods for treating T-cells. Also provided are methods of using the CD8 binding agents herein in methods for predicting the responsiveness of a subject with a disease (e.g., cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease) to treatment with an immunotherapeutic agent. In addition, methods of using the CD8 binding agents herein to monitor disease progression and / or treatment progress in a subject with a disease (e.g., cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease) who is receiving treatment with an immunotherapeutic agent are provided.
[0060] definition
[0061] The term "human CD8" herein refers to a protein, polypeptide or portion thereof corresponding to a human cluster of differentiation 8 molecule. Full-length human CD8 is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor. The human CD8 protein is a dimer consisting of a pair of CD8 chains, including CD8α and CD8β chains. The term "human CD8" includes CD8α / CD8α homodimers, CD8α / CD8β heterodimers, CD8α chains, CD8β chains or portions thereof, such as one or more extracellular domains. "CD8a" and "CD8α" are used interchangeably herein, and "CD8b" and "CD8β" are used interchangeably herein. An exemplary sequence of a human CD8α chain is shown in Figure 2 .
[0062] The term "CD8 binding agent" herein refers to any CD8 binding molecule. The CD8 binding agent can be a polypeptide, protein, antibody (including 4-chain antibody or heavy chain antibody), antibody fragment (e.g., VHH) or immunoconjugate that binds to human CD8, cynomolgus CD8 and / or other non-human CD8 proteins or peptides. The CD8 binding agent can also contain a label, such as a small molecule label, for example, a radionuclide. CD8 binding agents containing labels are also referred to herein as "labeled CD8 binding agents".
[0063] The term "antibody" herein is used in the broadest sense and includes various antibody structures, including but not limited to monoclonal antibodies, monovalent antibodies (e.g., one-armed antibodies), 4-chain antibodies (e.g., IgG antibodies), heavy chain antibodies and antibody fragments thereof, as long as they exhibit the desired antigen binding activity, i.e., binding to CD8 (e.g., human CD8, cynomolgus CD8 and / or rhesus CD8). The term "4-chain antibody" is used interchangeably herein to refer to an antibody or antigen-binding fragment having two heavy chains and two light chains.
[0064] "Antibody fragments" comprise a portion of an antibody, preferably the antigen binding region or variable region of an antibody. Examples of antibody fragments include VHHs, single domain antibodies, Fab, Fab', F(ab'), 2 and Fv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062
[1995] ); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The term "constant domain" refers to a portion of an immunoglobulin molecule that has a more conserved amino acid sequence than the variable domain of the rest of the immunoglobulin that contains the antigen binding site. The constant domain contains the C H 1. C H 2 and C H 3 domains (collectively referred to as C H ) and the CHL (or C L ) domain.
[0065] The term "Fc region" or "crystallizable segment region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, including a native sequence Fc region and a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from an amino acid residue at a position of Cys226 or Pro230 to its carboxyl terminus. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during the production or purification of the antibody, or by recombinant engineering of a nucleic acid encoding an antibody heavy chain. Thus, the composition of a complete antibody may include an antibody population from which all K447 residues have been removed, an antibody population from which the K447 residue has not been removed, and an antibody population containing a mixture of antibodies with and without the K447 residue. Suitable native sequence Fc regions for use with the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.
[0066] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerizations, amidations) that may be present in small amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Compared to polyclonal antibody preparations that generally include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous because they are synthesized by hybridoma cultures and are not contaminated by other immunoglobulins. The modifier "monoclonal" indicates the characteristic that an antibody is obtained from a substantially homogeneous antibody population, and should not be construed as requiring the antibody to be produced by any particular method. For example, the monoclonal antibodies used in accordance with the present application can be prepared by a variety of techniques, including, for example, the hybridoma method (e.g., Kohler and Milstein, Nature ,256:495-97 (1975); Hongo et al., Hybridoma ,14(3):253-260 (1995),Harlow et al. Antibodies: A Laboratory Manual , (Cold Spring Harbor Laboratory Press, 2nd edition, 1988); Hammerling et al., in Monoclonal Antibodies and T - Cell Hybridomas 563-681 (Elsevier, NY, 1981)), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567), phage display technology (see, e.g., Clackson et al., Nature , 352: 624-628(1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Sidhu et al. J. Mol. Biol. 338(2): 299-310 (2004); Lee et al. J. Mol. Biol. 340(5): 1073-1093 (2004);Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al., J. Immunol. Methods284(1-2): 119-132 (2004), and techniques for producing human or human-like antibodies in animals having human immunoglobulin loci or genes that partially or completely encode human immunoglobulin sequences (see, e.g., WO 1998 / 24893; WO 1996 / 34096; WO 1996 / 33735; WO 1991 / 10741; Jakobovits et al., Proc. Natl. Acad. Sci. USA 90: 2551 (1993); Jakobovits et al. Nature 362: 255-258 (1993); Bruggemann et al., Year in Immunol. 7:33 (1993); U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425 and 5,661,016; Marks et al. Bio / Technology 10:779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368:812-813 (1994); Fishwild et al., Nature Biotechnol. 14: 845-851 (1996); Neuberger, Nature Biotechnol. 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13:65-93 (1995).
[0067] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is associated with the binding of the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and Co., p. 91 (2007)). A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, VH or VL domains from antibodies that bind to antigens can be used to screen libraries of complementary VL or VH domains, respectively, to isolate antibodies that bind to specific antigens. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0068] The term "heavy chain antibody", also called "heavy chain only antibody" or "HCAb", refers to a functional antibody that contains two heavy chains but lacks the two light chains normally found in a 4-chain antibody. Camelids (such as camels, llamas or alpacas) are known to produce HCAbs.
[0069] The term "single domain antibody" or "sdAb" refers to a single antigen binding domain with three complementarity determining regions (CDRs). A single sdAb is capable of binding to an antigen without pairing with a corresponding CDR-containing polypeptide. In some cases, single domain antibodies are artificially engineered from camelid HCAbs and are referred to as "VHHs" (defined below). Camelid sdAb is one of the smallest known antigen-binding antibody fragments (see, e.g., Hamers-Casterman et al., Nature 363:446-8 (1993); Greenberg et al., Nature 374:168-73 (1995); Hassanzadeh-Ghassabeh et al., Nanomedicine (Lond), 8:1013-26 (2013)).
[0070] The term "VHH" or "variable domain of the heavy chain of a heavy chain antibody" refers to a single heavy chain variable domain of a heavy chain antibody. VHH molecules can be derived from Camelidae ( Camelidae ) species such as camel, alpaca, vicuna, dromedary, alpaca and guanaco. The basic VHH has the following structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1 to FR4 refer to framework regions 1 to 4, respectively, and wherein CDR1 to CDR3 refer to complementarity determining regions 1 to 3.
[0071] As used herein, the term "hypervariable region" or "HVR" refers to individual regions of an antibody variable domain that are highly variable in sequence ("complementarity determining regions" or "CDRs") and / or form structurally defined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contacts"). Typically, 4-chain antibodies and antigen-binding antibody fragments thereof comprise six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Typically, a heavy chain antibody comprises three HVRs (HVR1, HVR2, HVR3).
[0072] Many HVR descriptions are in use and are included herein. Exemplary HVRs of the 4-chain antibodies and antigen-binding antibody fragments thereof herein include: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest , 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)); (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262: 732-745 (1996)); and (d) a combination of (a), (b) and / or (c) comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3) and 94-102 (H3).
[0073] Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0074] The amino acid residues of a single domain antibody (such as VHH) can be determined according to the V given by Kabat et al. ("Sequence of proteins of immunological interest", US Public Health Services, NIH Bethesda, Md., Publication No. 91). HThe domains are numbered according to the common numbering as applied to VHH domains from Camelidae in Riechmann and Muyldermans, J. Immunol. Methods 2000 Jun 23; 240 (1-2): 185-195. According to said numbering, the FR1 of a VHH comprises the amino acid residues at positions 1-30, the CDR1 of a VHH comprises the amino acid residues at positions 31-35, the FR2 of a VHH comprises the amino acid residues at positions 36-49, the CDR2 of a VHH comprises the amino acid residues at positions 50-65, the FR3 of a VHH comprises the amino acid residues at positions 66-94, the CDR3 of a VHH comprises the amino acid residues at positions 95-102, and the FR4 of a VHH comprises the amino acid residues at positions 103-113. In this regard, it should be noted that - as is known in the art for V H As is well known in the art, the total number of amino acid residues in each CDRs may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering (i.e., one or more positions according to the Kabat numbering may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed by the Kabat numbering).
[0075] "Framework" or "FR" residues are those variable domain residues other than the HVR residues as defined herein.
[0076] The term "chimeric" antibody refers to an antibody in which a portion of the heavy chain and / or light chain is identical to or derived from a particular source or species, while the remainder of the heavy chain and / or light chain is identical to or derived from a different source or species.
[0077] "Humanized" antibodies are antibodies containing minimal sequences derived from non-human antibodies. Generally, humanized antibodies are human immunoglobulins (receptor antibodies), wherein residues from the receptor hypervariable region are replaced by residues from the hypervariable region of non-human species (donor antibodies) such as camelids, mice, rats, rabbits or non-human primates with desired antibody specificity, affinity and ability. In certain aspects, "humanized" antibodies refer to chimeric antibodies comprising amino acid residues from non-human (e.g., camelids) CDRs and amino acid residues from human FRs. In some cases, the framework region (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. In addition, humanized antibodies may be included in residues not found in the receptor antibody or the donor antibody. These modifications are carried out to further improve antibody performance. Generally, humanized antibodies will comprise substantially all at least one, and generally two variable domains, wherein all or substantially all of the hypervariable loops correspond to those of non-human immunoglobulins, and all or substantially all of the FRs are those of human immunoglobulin sequences. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
[0078] An "affinity matured" antibody is one that has one or more alterations in one or more of its CDRs that result in an improvement in the affinity of the antibody for an antigen, compared to a parent antibody that does not have those alterations or alterations. In some embodiments, affinity matured antibodies have nanomolar or even picomolar affinities for a target antigen. Affinity matured antibodies are produced by procedures known in the art. For example, random mutagenesis of CDR and / or framework residues is described in, e.g., Barbas et al., Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al. Gene 169:147-155(1995); Yelton et al., J. Immunol. 155:1994-2004 (1995); Jackson et al. J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).
[0079] "Percent (%) amino acid sequence identity" or "homology" with respect to the polypeptide and antibody sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the polypeptide being compared, after aligning the sequences, considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the sequences being compared. However, for purposes of this article, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code has been submitted with user documentation to the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[0080] As used herein, the term "specifically binds" or "specifically binds to" or "is specific for" a particular polypeptide or an epitope on a particular polypeptide target can be, for example, by having at least about 10 -4 M, on the other hand at least about 10 -5 M, on the other hand at least about 10 -6 M, on the other hand at least about 10 -7 M, on the other hand at least about 10 -8 M, on the other hand at least about 10 -9 M, on the other hand at least about 10 -10 M, on the other hand at least about 10 -11 M, on the other hand at least about 10 -12 M or greater for the target K D In some embodiments, the term "specific binding" refers to the binding of a molecule to a specific polypeptide or an epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope. DCan be determined by methods known in the art, such as ELISA, surface plasmon resonance (SPR), fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA). For example, specific binding can be measured by determining the binding of a molecule compared to the binding of a control molecule, which is generally a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule similar to the target, for example, an excess of unlabeled target. In this case, if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target, specific binding is indicated.
[0081] As used herein, "treatment" or "treating" is a method for obtaining beneficial or desired results including clinical results. For the present application, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms caused by the disease, reducing the degree of the disease, stabilizing the disease (e.g., preventing or delaying the deterioration of the disease), preventing or delaying the spread of the disease (e.g., metastasis), preventing or delaying the recurrence of the disease, delaying or slowing down the progress of the disease, improving the disease state, providing relief (partial or complete) of the disease, reducing the dosage of one or more other medications required for the treatment of the disease, delaying the progress of the disease, increasing or improving the quality of life, increasing weight gain and / or prolonging survival. "Treatment" also includes reducing the pathological consequences of cancer (e.g., such as tumor volume). The method provided herein contemplates any one or more of these treatment aspects.
[0082] An "effective amount" of a CD8 binding agent or composition as disclosed herein is an amount sufficient to achieve a specified stated purpose, e.g., to activate CD8 in vivo. + T-cell imaging. An "effective amount" can be determined empirically and by comparing the amount with the stated purpose (e.g., in vivo CD8 + T-cell imaging) related methods.
[0083] The term "therapeutically effective amount" refers to an amount of, for example, an immunotherapeutic agent (e.g., an immunotherapeutic agent described elsewhere herein), a cell therapy, or a cancer vaccine that is effective in "treating" a disease or condition in a subject (e.g., a mammal, such as a human). In the case of cancer, a therapeutically effective amount of an immunotherapeutic agent, a cell therapy, or a cancer vaccine can reduce the number of cancer cells; reduce tumor size or weight; inhibit (e.g., slow down and preferably stop to some extent) cancer cell infiltration to surrounding organs; inhibit (e.g., slow down and preferably stop to some extent) tumor metastasis; inhibit tumor growth to some extent; and / or alleviate one or more symptoms associated with cancer to some extent. Insofar as an immunotherapeutic agent, a cell therapy, or a cancer vaccine can prevent growth and / or kill existing cancer cells, it can be cytostatic and / or cytotoxic. In some embodiments, the therapeutically effective amount is a growth inhibitory amount. In another embodiment, the therapeutically effective amount is an amount that prolongs patient survival. In another embodiment, the therapeutically effective amount is an amount that improves patient progression-free survival.
[0084] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as rhesus monkeys and cynomolgus monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the individual or subject is a human.
[0085] As used herein, "responsiveness" refers to the occurrence of a favorable response when a subject is or has been treated with a therapeutic agent (e.g., an immunotherapeutic agent). An example of a favorable response is inhibition of tumor growth in a subject during or after treatment with a therapeutic agent (e.g., an immunotherapeutic agent), while an unfavorable example is continued growth or accelerated growth of a tumor in a subject during or after treatment with a therapeutic agent (e.g., an immunotherapeutic agent).
[0086] As used herein, "monitoring disease progression" refers to evaluating a subject (e.g., a subject diagnosed with cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease) at serial time intervals to determine whether disease symptoms have worsened, stabilized, or improved (i.e., become less severe). For example, in some cases, monitoring a subject's cancer progression may include monitoring changes in tumor weight or size (e.g., tumor regression or tumor growth), time to progression, duration of survival, length of progression-free survival, overall response rate, duration of response, quality of life, expression and / or activity of disease markers (e.g., expression of certain genes and / or proteins), or other criteria known in the art. Additional methods may be employed to monitor disease progression in cancer patients, including, for example, measuring response to treatment by imaging techniques, which will be described in further detail elsewhere herein.
[0087] As used herein, "monitoring treatment progress" refers to evaluating a subject (e.g., a subject diagnosed with cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease) at serial time intervals during or after treatment (e.g., treatment with an immunotherapeutic agent) to determine whether disease symptoms have worsened, stabilized, or improved (i.e., become less severe) as a result of treatment. For example, treatment progress in a subject (e.g., a subject who has been or is being treated with an immunotherapeutic agent) can be monitored using the same criteria as those used to monitor disease progression.
[0088] As used herein, "pharmaceutically acceptable" or "pharmacologically compatible" means a material that is not biologically or otherwise undesirable, e.g., the material can be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effect or interacting in a deleterious manner with any other component of the composition containing it. Pharmaceutically acceptable carriers or excipients preferably meet the standards of toxicology and manufacturing testing requirements and / or are included in the Inactive Ingredient Guide established by the US Food and Drug Administration.
[0089] As used herein, "in conjunction with" refers to the timing of administration of a CD8 binding agent, such as described herein, relative to administration of a second agent, such as an immunotherapeutic agent or another diagnostic imaging agent. For example, administration of a CD8 binding agent, such as described herein, together with an immunotherapeutic agent means that the CD8 binding agent can be administered before the immunotherapeutic agent has been administered, after the immunotherapeutic agent has been administered, simultaneously with the administration of the immunotherapeutic agent, or synchronously with the administration of the immunotherapeutic agent. The additional agent can be administered before or after the administration of the CD8 binding agent and the immunotherapeutic agent. Additionally or alternatively, the other agent can be administered between the sequential administration of the CD8 binding agent and the immunotherapeutic agent.
[0090] The term "detection" is intended to include determining the presence or absence of a substance or quantifying the amount of a substance (e.g., CD8). Therefore, the term refers to the use of the materials, compositions, and methods of the present application for qualitative and quantitative determination. Generally, the specific technique used for detection is not critical to the practice of the methods in the present application. For example, "detection" according to the methods described herein may include observing the presence or absence of a CD8 polypeptide or a change in the level of a CD8 polypeptide. In some embodiments, "detection" may include detecting wild-type CD8 levels (e.g., mRNA or polypeptide levels). When compared to a control, detection may include quantifying any value between 10% and 90%, or any value between 30% and 60%, or a change (increase or decrease) of more than 100%. Detection may include quantifying a change in any value between 2-fold and 10-fold (including the endpoints) or more, such as 100-fold.
[0091] As used herein, the term "label" refers to a detectable compound or composition that is conjugated directly or indirectly to an antibody (e.g., VHH). The label itself can be independently detectable (e.g., radioisotope labels or fluorescent labels), or in the case of an enzymatic label, can catalyze chemical alteration of a detectable substrate compound or composition.
[0092] References herein to "about" values or parameters refer to the usual error ranges for the corresponding values that are readily known to those skilled in the art. References herein to "about" values or parameters include (and describe) aspects related to the value or parameter itself. For example, a description referring to "about X" includes a description of "X".
[0093] It should be understood that aspects and embodiments of the present application include "comprising," "consisting of," and "consisting essentially of" the aspects and embodiments.
[0094] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0095] As used herein, the term "and / or", phrases such as "A and / or B", are intended to include both A and B; A or B; A (alone); and B (alone). Similarly, as used herein, the term "and / or", phrases such as "A, B, and / or C", are intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0096] It should be understood that certain features of the invention described in the context of separate embodiments for the sake of clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of a single embodiment for the sake of brevity may also be provided separately or in any suitable subcombination. All combinations of embodiments related to CD8 binders and methods of use thereof are expressly included in the invention and disclosed herein, just as each combination is individually and expressly disclosed herein.
[0097] CD8 binders
[0098] a. Functional characteristics
[0099] The CD8-binding agents provided herein comprise a VHH domain (e.g., a camelid or humanized VHH) and have one or more of the following characteristics: (a) the CD8-binding agent has a K of about 1 nM or less; D (b) the CD8 binding agent binds specifically to human CD8 with a k of about 0.002 / s or less (e.g., about 0.0018 / s, or about 0.00085 / s) off Binds to human CD8; (c) CD8 binders with a K of about 1 nM or less D (d) the CD8 binder binds to cynomolgus monkey CD8 with a k of about 0.004 / s or less (e.g., about 0.0037 / s, or about 0.0019 / s); off Binds to cynomolgus monkey CD8; (e) CD8 binders do not inhibit or stimulate CD8 + T cell activation; (f) CD8 binders do not induce CD8 + T cell proliferation; and (g) CD8 binders do not bind CD4 + Cells. In some embodiments, the VHH domain has one or more features of a CD8 binding agent described herein. In some embodiments, a labeled VHH domain (i.e., a VHH domain conjugated to a detectable label) has one or more features of a CD8 binding agent described herein.
[0100] The CD8 binding agents described herein bind CD8 with high affinity and specificity. In some embodiments, the CD8 binding agent is present at about 1 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.25 nM, 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, 0.02 nM, 0.01 nM, 0.001 nM or less (e.g., 10 -9 M or smaller, e.g. 10 -9 M-10 -13 M or 10 -10 M-10 -12M) K D Binds to human CD8, including any value or range between these values. In some embodiments, the CD8 binding agent is present at about 1 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.25 nM, 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, 0.02 nM, 0.01 nM, 0.001 nM or less (e.g., 10 -9 M or smaller, e.g. 10 -9 M-10 -13 M or 10 -10 M-10 -12 M) K D Binds to rhesus CD8, including any value or range between these values. In some embodiments, the CD8 binding agent is present at 1 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.25 nM, 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, 0.02 nM, 0.01 nM, 0.001 nM or less (e.g., 10 -9 M or smaller, e.g. 10 -9 M-10 -13 M or 10 -10 M-10 -12 M) K D Binds to cynomolgus monkey CD8, including any value or range between these values. In some embodiments, the CD8 binding agent (a) is present at about 1 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.25 nM, 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, 0.02 nM, 0.01 nM, 0.001 nM or less (e.g., 10 -9 M or smaller, e.g. 10 -9 M-10 -13 M or 10 -10 M-10 -12 M) K D binds to human CD8, including any value or range between these values; (b) at about 1 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.25 nM, 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, 0.02 nM, 0.01 nM, 0.001 nM or less (e.g., 10 -9 M or smaller, e.g. 10 -9 M-10 -13 M or 10 -10 M-10 -12 M) K Dbinds to rhesus monkey CD8, including any value or range between these values, and (c) at about 1 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.25 nM, 0.2 nM, 0.15 nM, 0.1 nM, 0.05 nM, 0.02 nM, 0.01 nM, 0.001 nM or less (e.g., 10 -9 M or smaller, e.g. 10 -9 M-10 -13 M or 10 -10 M-10 -12 M) K D Binds to cynomolgus monkey CD8, including any value or range between these values. In some embodiments, the CD8 binding agent has a K of about 150 pM or less. D binds human CD8, and the CD8 binder has a K of about 350 pM or less D Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent has a K of about 132 pM D Binds to human CD8, and the CD8 binder has a K of approximately 344 pM D Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent has a K of about 50 pM or less. D binds human CD8, and the CD8 binder has a K of about 150 pM or less D Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 with a K of about 50 pM. D Binds to human CD8, and the CD8 binder has a K of approximately 137 pM D Binds to cynomolgus monkey CD8. In some embodiments, CD8 is CD8α. In some embodiments, CD8 is a CD8α / CD8α homodimer. In some embodiments, CD8 is a CD8α / CD8β heterodimer.
[0101] In some embodiments, the CD8 binding agent is transmitted at a rate of about 0.01 / s, 0.005 / s, 0.004 / s, 0.003 / s, 0.002 / s, 0.0015 / s, 0.001 / s, 0.0005 / s, 0.0002 / s, 0.0001 / s or less (e.g., 10 -2 / s or less, such as 10 -5 / s-10 -2 / s or 10 -4 -10 -3 / s) offBinds to human CD8, including any value or range between these values. In some embodiments, the CD8 binding agent is at about 0.01 / s, 0.005 / s, 0.002 / s, 0.001 / s, 0.0005 / s, 0.004 / s, 0.003 / s, 0.002 / s, 0.0015 / s, 0.001 / s, 0.0005 / s or less (e.g., 10 -2 / s or less, such as 10 -5 / s -10 -2 / s or 10 -4 -10 -3 / s) off Binds to rhesus CD8, including any value or range between these values. In some embodiments, the CD8 binding agent is at about 0.01 / s, 0.005 / s, 0.002 / s, 0.001 / s, 0.0005 / s, 0.004 / s, 0.003 / s, 0.002 / s, 0.0015 / s, 0.001 / s, 0.0005 / s or less (e.g., 10 -2 / s or less, such as 10 -5 / s -10 -2 / s or 10 -4 -10 -3 / s) off Binds to cynomolgus monkey CD8, including any value or range between these values. In some embodiments, the CD8 binding agent (a) is present at about 0.01 / s, 0.005 / s, 0.004 / s, 0.003 / s, 0.002 / s, 0.0015 / s, 0.001 / s, 0.0005 / s, 0.0002 / s, 0.0001 / s or less (e.g., 10 -2 / s or less, such as 10 -5 / s-10 -2 / s or 10 -4 -10 -3 / s) off (b) binds to human CD8, including any value or range between these values; (c) at about 0.01 / s, 0.005 / s, 0.002 / s, 0.001 / s, 0.0005 / s, 0.004 / s, 0.003 / s, 0.002 / s, 0.0015 / s, 0.001 / s, 0.0005 / s or less (e.g., 10 -2 / s or less, such as 10 -5 / s -10 -2 / s or 10 -4 -10 -3 / s) offBinds to rhesus monkey CD8, including any value or range between these values; (c) at about 0.01 / s, 0.005 / s, 0.002 / s, 0.001 / s, 0.0005 / s, 0.004 / s, 0.003 / s, 0.002 / s, 0.0015 / s, 0.001 / s, 0.0005 / s or less (e.g., 10 -2 / s or less, such as 10 -5 / s -10 -2 / s or 10 -4 -10 -3 / s) off Binds to cynomolgus monkey CD8, including any value or range between these values. In some embodiments, the CD8 binding agent has a k of about 0.002 / s or less. off binds to human CD8, and the CD8 binding agent has a k of about 0.004 / s or less off Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 at a k of about 0.0018 / s. off Binds to human CD8, and the CD8 binder has a k of about 0.0037 / s off Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 at a k of about 0.001 / s. off Binds to human CD8, and the CD8 binder has a k of about 0.002 / s off Binds to cynomolgus monkey CD8. In some embodiments, the CD8 binding agent binds to cynomolgus monkey CD8 at a k of about 0.00085 / s. off Binds to human CD8, and the CD8 binder has a k of about 0.0019 / s off Binds to cynomolgus monkey CD8. In some embodiments, CD8 is CD8α. In some embodiments, CD8 is a CD8α / CD8α homodimer. In some embodiments, CD8 is a CD8α / CD8β heterodimer.
[0102] In some embodiments, the CD8 binding agent binds to human CD8 with a CD8-binding half-life (e.g., in an in vitro binding assay) of about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours or longer (e.g., at least 15 minutes, such as 15 minutes-6 hours or 30 minutes-2 hours), including any values or ranges between these values. In some embodiments, the CD8 binding agent binds to rhesus CD8 with a CD8-binding half-life of about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours or longer (e.g., at least 15 minutes, such as 15 minutes-6 hours or 30 minutes-2 hours), including any values or ranges between these values. In some embodiments, the CD8 binding agent binds to cynomolgus CD8 with a CD8-binding half-life of about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours or longer (e.g., at least 15 minutes, such as 15 minutes-6 hours or 30 minutes-2 hours), including any values or ranges between these values.
[0103] The CD8 binding agents provided herein are K-binding agents for human CD8, rhesus CD8 and / or cynomolgus CD8. D and k off The K of a CD8 binding agent provided herein to human CD8, rhesus CD8 and / or cynomolgus CD8 can be determined by any method known in the art, including, but not limited to, for example, ELISA, fluorescence activated cell sorting (FACS) analysis, radioimmunoprecipitation (RIA), and surface plasmon resonance (SPR). D and / or k off By SPR determination. In some embodiments, the K of the CD8 binding agents provided herein is D and / or k off By surface plasmon resonance (SPR) assay using CD8α / CD8β-Fc fusion protein as a reagent. In some embodiments, the CD8α / CD8β-Fc fusion protein is a one-armed human CD8α / human CD8β-Fc fusion protein. In some embodiments, the CD8α / CD8β-Fc fusion protein is a one-armed cynomolgus CD8α / cynomolgus CD8β-Fc fusion protein. In some embodiments, the one-armed CD8α / CD8β-Fc fusion protein comprises a single-chain polypeptide comprising human CD8α and human CD8β, which is fused to one polypeptide chain of Fc. In some embodiments, the one-armed CD8α / CD8β-Fc fusion protein comprises a single-chain polypeptide comprising cynomolgus CD8α and cynomolgus CD8β, which is fused to one polypeptide chain of Fc. In some embodiments, the CD8 binding agent provided herein is for the K of human CD8, rhesus CD8 and / or cynomolgus CD8 D Determined by FACS. Exemplary human, rhesus and cynomolgus CD8α amino acid sequences are shown in Figure 2 middle.
[0104] In some embodiments, the CD8 binding agents provided herein do not bind (e.g., specifically bind) mouse CD8. In some embodiments, the CD8 binding agents do not bind (e.g., specifically bind) rat CD8. In some embodiments, the CD8 binding agents do not bind (e.g., specifically bind) mouse CD8 or rat CD8, e.g., as determined by SPR and / or FACS.
[0105] The characteristics of the CD8 binding agents described herein can be assessed using well-known methods, for example, the methods used in the following embodiments. In some embodiments, CD8 binding is assessed in vitro in the presence of peripheral blood mononuclear cells (PBMCs) and a CD8 binding agent provided herein. + T cell proliferation. In some embodiments, CD8 is assessed in vitro in the presence of PBMCs, anti-CD3 antibodies, anti-CD28 antibodies, and CD8 binding agents provided herein. + T cell proliferation. In some embodiments, in the presence of Staphylococcus aureus ( Staphylococcus In vitro evaluation of CD8 in the presence of PBMCs stimulated with enterotoxin B (SEB) and the CD8 binding agents provided herein + T cell proliferation. In some embodiments, CD8 is assessed in vitro in the presence of PBMCs stimulated with a CEF peptide library and a CD8 binding agent provided herein. + T cell proliferation. In some embodiments, CD8 is assessed in vitro in the presence of PBMCs stimulated with lipopolysaccharide (LPS) and a CD8 binding agent provided herein. + T cell proliferation. In some embodiments, the in vitro assay is performed using 10% FBS as culture medium. In some embodiments, the in vitro assay is performed using 10% autologous donor plasma as culture medium, wherein the donor plasma and PBMCs are obtained from the same donor.
[0106] In some embodiments, the CD8 binding agents provided herein do not bind (e.g., specifically bind) human CD4 + In some embodiments, the CD8 binding agents provided herein do not bind (e.g., specifically bind) human CD3 - In some embodiments, the CD8 binding agents provided herein do not bind (e.g., specifically bind) human CD4 + T cells or human CD3 - In some embodiments, the lack of specific binding of a CD8 binding agent provided herein to human CD4+ T cells or human CD3- cells is detected by fluorescence activated cell sorting (FACS), as discussed in the Examples.
[0107] Provided herein are exemplary CD8 binding agents (including anti-CD8 antibodies and antibody fragments thereof) having one or more of the above functional characteristics. In some embodiments, a CD8 binding agent comprising a VHH domain is provided, wherein the domain specifically binds to a human CD8α epitope comprising Arg25, Lys42, Gln44, Val45, Leu46, Leu47, Ser48, Pro50, Thr51, Ser52, Gln75, Arg93, Leu94, Gly95, Asp96, and Thr97, wherein the amino acid numbering is according to SEQ ID NO: 13. Also provided are human CD8α epitopes comprising Arg25, Lys42, Gln44, Val45, Leu46, Leu47, Ser48, Pro50, Thr51, Ser52, Gln75, Arg93, Leu94, Gly95, Asp96, and Thr97, wherein the amino acid numbering is according to SEQ ID NO: 13. In some embodiments, the amino acid residues in the human CD8α epitope are within about 4.5 Å from one or more amino acid residues of a VHH domain in a crystal structure of a CD8 binding agent or VHH domain that binds to human CD8α. Further provided are anti-CD8 antibodies that competitively bind to the same human CD8α epitope as any of the CD8 binding agents (e.g., anti-CD8 VHHs) described herein.
[0108] In some embodiments, the CD8 binding agents provided herein comprise a camelid VHH domain that specifically binds to human CD8. In some embodiments, the CD8 binding agents provided herein comprise a humanized VHH domain that specifically binds to human CD8.
[0109] In some embodiments, a CD8 binding agent comprising a VHH domain is provided, wherein the VHH domain comprises at least one, two or three CDRs of the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
[0110] In some embodiments, a CD8-binding agent is provided that comprises a VHH domain, wherein the VHH domain comprises at least one, two or three CDRs selected from the following: (a) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 7; (b) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 8 or SEQ ID NO: 9; and (c) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.
[0111] In some embodiments, a CD8-binding agent is provided that comprises a VHH domain, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7; a CDR2 comprising the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12.
[0112] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises CDR1, CDR2 and CDR3 in the amino acid sequence of SEQ ID NO: 1.
[0113] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises CDR1, CDR2 and CDR3 in the amino acid sequence of SEQ ID NO: 2.
[0114] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises CDR1, CDR2, and CDR3 in the amino acid sequence of SEQ ID NO: 3.
[0115] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises CDR1, CDR2, and CDR3 in the amino acid sequence of SEQ ID NO: 4.
[0116] In some embodiments, a CD8 binding agent comprising a VHH domain is provided, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0117] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11.
[0118] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11.
[0119] In some embodiments, a CD8-binding agent comprising a VHH domain is provided, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12.
[0120] Exemplary CDR sequences are shown in Figure 1 and Table 1 below.
[0121] Table 1
[0122]
[0123] In some embodiments, the CD8 binding agent comprises a VHH domain comprising L49A, wherein numbering is according to Kabat numbering. An example of an L49A mutation is shown in Figure 1 In some embodiments, the L49A mutation allows the CD8 binding agent to be purified using a protein A column. In some embodiments, the L49A mutation increases the yield of the CD8 binding agent by at least about 2-fold, 5-fold, 10-fold or more.
[0124] In some embodiments, a CD8-binding agent comprises a VHH domain comprising one or more framework mutations that reduce the immunogenicity of the VHH domain, e.g., reduce binding of the CD8-binding agent to a pre-existing anti-VHH antibody in a subject receiving the CD8-binding agent. In some embodiments, a CD8-binding agent comprises a VHH domain comprising one or more amino acid modifications selected from a V89T substitution, a T110Q substitution, a S112Q substitution, and an A114 addition, wherein the numbering is according to Kabat numbering. In some embodiments, a VHH domain comprises a V89T substitution, a T110Q substitution, a S112Q substitution, and an A114 addition, wherein the numbering is according to Kabat numbering. Examples of these mutations are shown in Figure 1 In some embodiments, the framework mutations reduce the immunogenicity of the CD8 binding agent by at most about 1 / 2, 1 / 10, 1 / 100, 1 / 1000 or less.
[0125] In some embodiments, the CD8 binding agent comprises a VHH domain having the amino acid sequence of SEQ ID NO: 1. In some embodiments, the CD8 binding agent comprises a VHH domain having the amino acid sequence of SEQ ID NO: 2. In some embodiments, the CD8 binding agent comprises a VHH domain having the amino acid sequence of SEQ ID NO: 3. In some embodiments, the CD8 binding agent comprises a VHH domain having the amino acid sequence of SEQ ID NO: 4.
[0126] Exemplary VHH sequences are shown in Figure 1 middle.
[0127] In some embodiments, the CD8 binding agents provided herein are cleared renally. In some embodiments, the CD8 binding agents provided herein are cleared (eg, primarily cleared) by the renal system.
[0128] In some embodiments, anti-CD8 antibodies are provided. In some embodiments, anti-CD8 heavy chain antibodies comprising any of the VHH domains described herein are provided. In some embodiments, the anti-CD8 heavy chain antibodies comprise an Fc region, such as a camelid or human Fc region. In some embodiments, the anti-CD8 heavy chain antibodies comprise an Fc or variant thereof of IgG1, IgG2, IgG3, or IgG4. In some embodiments, the anti-CD8 antibodies provided herein comprise Fc variants having some but not all effector functions, making them desirable candidates for applications where the half-life of the antibody in vivo is important but certain effector functions (e.g., complement and ADCC) are unnecessary or deleterious.
[0129] In some embodiments, anti-CD8 antibody fragments are provided, such as anti-CD8 single domain antibodies or anti-CD8 VHHs.
[0130] In some embodiments, the CD8 binding agent does not comprise an Fc region.
[0131] In some embodiments, the CD8 binding agents provided herein include one or more non-protein moieties. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers) and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol (propropylene glycol) homopolymers, polypropylene oxide / ethylene oxide copolymers (prolypropylene oxide / ethylene oxide co-polymers), polyoxyethylene polyols (e.g., glycerol), polyvinyl alcohol and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may have any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization may be determined based on considerations including, but not limited to, the particular property or function of the antibody to be improved, whether the antibody derivative will be used for treatment under a specified condition, etc.
[0132] In some embodiments, the CD8 binding agent does not comprise a non-protein moiety that increases the serum half-life of the agent. In some embodiments, the CD8 binding agent does not comprise a soluble polymer, such as polyethylene glycol (PEG).
[0133] b. Variants and Modifications
[0134] In some embodiments, amino acid sequence variants of the CD8 binding agents (e.g., anti-CD8 antibodies) described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the CD8 binding agent. Amino acid sequence variants of the CD8 binding agent can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the protein, or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the CD8 binding agent (e.g., in one or more CDRs and / or framework sequences or in the VHH domain). Any combination of deletions, insertions, and substitutions may be performed to obtain a final construct, as long as the final construct has the desired characteristics (e.g., as described elsewhere herein).
[0135] By "CD8 binding agent variant" is meant a polypeptide, e.g., a CD8 binding agent having the desired characteristics described herein comprising a VHH having at least about 80% amino acid sequence identity with a VHH of a CD8 binding agent described herein. Such CD8 binding agent variants include, for example, agents in which one or more amino acid residues are added to or deleted from a VHH domain. Typically, a CD8 binding agent variant will have at least about 80% amino acid sequence identity with a CD8 binding agent described herein, and in another aspect at least about any of 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity. Optionally, a variant CD8 binding agent will have no more than one conservative amino acid substitution compared to a CD8 binding agent sequence provided herein, and in another aspect no more than about any of 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions compared to a CD8 binding agent sequence provided herein.
[0136] In some embodiments, CD8 binder variants having one or more amino acid substitutions, insertions and / or deletions are provided. Sites of interest for substitution mutagenesis include HVRs and FRs. Conservative substitutions are shown in Table 2 under the heading "Conservative Substitutions". More substantial changes are provided in Table 2 under the heading "Exemplary Substitutions" and as further described below with respect to amino acid side chain classes. Amino acid substitutions can be introduced into an antibody of interest, and the product can be screened for desired activity, e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0137] Table 2
[0138]
[0139]
[0140] Substantial modification of the biological properties of the CD8 binding agent variants can be accomplished by selecting substitutions that differ significantly in their effects on maintaining: (a) the structure of the polypeptide backbone in the area of the substitution, e.g., as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Amino acids can be grouped according to similarities in the properties of their side chains (in AL Lehninger, Biochemistry 2nd ed., pp. 73-75, Worth Publishers, New York (1975)):
[0141] (1) Non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M)
[0142] (2) Uncharged polarity: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q)
[0143] (3) Acidic: Asp (D), Glu (E)
[0144] (4) Alkalinity: Lys (K), Arg (R), His (H)
[0145] On the other hand, naturally occurring residues can be grouped based on common side chain properties:
[0146] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;
[0147] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;
[0148] (3) Acidic: Asp, Glu;
[0149] (4) Basic: His, Lys, Arg;
[0150] (5) Residues that affect chain orientation: Gly, Pro;
[0151] (6) Aromatic: Trp, Tyr, Phe.
[0152] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0153] In some embodiments, the CD8 binding agents provided herein comprise a VHH domain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the CD8 binding agents provided herein comprise a VHH domain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the CD8 binding agents provided herein comprise a VHH domain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the CD8 binding agents provided herein comprise a VHH domain comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the VHH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity contains substitutions (e.g., conservative substitutions), insertions or deletions relative to the reference sequence, but the CD8 binding agent comprising the sequence retains the ability to bind to CD8 (e.g., human CD8, rhesus CD8 and / or cynomolgus CD8). In some embodiments, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. In some embodiments, the substitutions, insertions or deletions occur in regions outside of the CDRs (i.e., in the FRs). In some embodiments, the CD8 binding agent comprises the VHH sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, including post-translational modifications of said sequence.
[0154] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., alpaca VHH or humanized VHH). Typically, one or more resulting variants selected for further study will have modifications (e.g., improvements) in certain biological properties relative to the parent antibody (e.g., increased affinity, reduced immunogenicity) and / or will substantially retain certain biological properties of the parent antibody. Exemplary substitution variants are affinity-matured antibodies that can be conveniently produced, for example, using affinity maturation techniques based on phage display, such as those described herein. In short, one or more HVR residues are mutated, and the variant antibodies are displayed on phage and screened for specific biological activity (e.g., binding affinity).
[0155] For example, changes (e.g., substitutions) can be made in HVRs to improve antibody affinity. Such changes can be made in HVR "hot spots", i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)) and / or SDRs (a-CDRs), and the resulting variant VHHs are tested for binding affinity. Affinity maturation by construction of a second library and reselection from the second library has been described, for example, in Hoogenboom et al., Methods in Molecular Biology 178: 1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A second library is then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method of introducing diversity involves an HVR-directed approach in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues associated with antigen binding can be specifically identified, for example, using alanine-scanning mutagenesis or modeling. CDR3 is often targeted in particular.
[0156] In some embodiments, substitutions, insertions or deletions may occur within one or more CDRs, as long as such changes do not significantly reduce the ability of the CD8 binder to CD8. For example, conservative changes that do not significantly reduce binding affinity (e.g., conservative substitutions as provided herein) may be made in the CDRs. Such changes may be outside of CDR "hot spots" or SDRs. In some embodiments of the variant VHH sequences provided above, each HVR is either unchanged or contains no more than one, two or three amino acid substitutions.
[0157] As Cunningham and Wells (1989) Science , 244:1081-1085, a useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine partitioning mutagenesis". In the method, residues or groups of target residues (e.g., charged residues such as Arg, Asp, His, Lys and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction between the antibody and the antigen is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. On the other hand or in addition, the crystal structure of the antigen-antibody complex is used to identify contact points between the antibody and the antigen. Such contact residues and adjacent residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain the desired properties.
[0158] Amino acid sequence insertions include amino and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertion variants of the antibody molecule include fusion of the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide that increases the serum half-life of the antibody.
[0159] c. Immunoconjugates containing detectable labels
[0160] In some embodiments, the CD8 binding agent is an immunoconjugate comprising any of the anti-CD8 antibodies described herein (e.g., anti-CD8 VHH) conjugated to a detectable label. The term "label" or "detectable label" refers to an atom, molecule, or compound that can be used for diagnosis, detection, or display / imaging of the location and / or amount of a target molecule (e.g., CD8) on a cell, tissue, organ, or the like. Detectable labels that can be used according to the embodiments herein include, but are not limited to, radioactive substances (e.g., radioisotopes, radionuclides, radiolabels, or radiotracers), dyes (e.g., Indocyanine Green (ICG)), contrast agents, fluorescent compounds or molecules, bioluminescent compounds or molecules, enzymes, and enhancing agents (e.g., paramagnetic ions). In addition, some nanoparticles, such as quantum dots and metal nanoparticles, may be suitable for use as detection agents.
[0161] Radioactive materials that can be used as detectable labels according to embodiments herein include, but are not limited to, 18 F. 32 P. 33 P.45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Sc, 77 As, 86 Y. 89 Sr. 89 Zr, 90 Y. 90 Nb, 94 Tc, 99 Tc, 99 mTc, 99 Mo, 105 Pd, 105 Rh, 111 Ag, 111 In, 123 I. 124 I. 125 I. 131 I. 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 169 2. 175 Lu, 177 Lu, 186 Re, 188 Re, 189 Re, 194 Ir, 198 Au, 199 Au, 211 At 211 Pb, 212 Bi, 212 Pb, 213 Bi, 223 Ra and 225 Ac. Exemplary paramagnetic ionic species that can be used as detectable labels include, but are not limited to, ions of transition metals and lanthanide metals (e.g., metals having atomic numbers of 6-9, 21-29, 42-44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.
[0162] When the detectable label is a radioactive metal or paramagnetic ion, in some embodiments, the label can react with a reagent having a long tail, and one or more chelating groups are attached to the long tail for binding these ions. The long tail can be a polymer, such as a polylysine, a polysaccharide, or other derivative or derivatizable chain with a side group that can bind a chelating group (i.e., for binding ions). Examples of chelating groups that can be used according to embodiments of the present invention include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), DOTA, NOIA, NOGADA, NETA, NODA, NOTA, deferoxamine (DfO), DFO* (i.e., DFO-asterisk), DFO-squaramide, porphyrin, polyamine, crown ether, bis-thiosemicarbazone, polyoxime, and similar groups. Chelates can be connected to anti-CD8 antibodies (e.g., anti-CD8 VHH) provided herein by allowing a group that forms a bond with the molecule with minimal loss of immunoreactivity and minimal aggregation and / or internal cross-linking. When used with the CD8 binding agents described herein, the same chelates can be used for magnetic resonance imaging (MRI) when complexed with non-radioactive metals (e.g., manganese, iron, and gadolinium). Macrocyclic chelates such as NOIA, NOGADA, DOTA, NODA, NOTA, and TETA are used for use with a variety of metals and radioactive metals, including, but not limited to, for example, radionuclides of gallium, yttrium, and copper. Other cyclic chelates can be used, such as macrocyclic polyethers, which are of interest for stably binding radionuclides such as radium-223 for radioiodine therapy (RAIT). In some embodiments, the chelating moiety can be used to bind positron emission tomography (PET) imaging agents, such as aluminum- 18 The F complex is attached to a CD8 binder provided herein for use in PET analysis. 18 The F complex can be conjugated to the VHH domain via a restrained complexing agent (RESCA), such as a compound of formula (I):
[0163] .
[0164] See, e.g., US20180273441A1 and Cleeren F. et al., Nature Protocols 13, 2330-2347 (2018).
[0165] In some embodiments, a CD8 binding agent is provided that comprises a radionuclide labeled with 18In some embodiments, the VHH domain is conjugated to a label via a chelating moiety. In some embodiments, the chelating moiety is covalently linked to the VHH domain via a lysine residue. In some embodiments, the radionuclide label is contained in a metal complex. In some embodiments, the radionuclide label forms a complex with the metal, wherein the complex is chelated by the chelating moiety. In some embodiments, the CD8 binding agent comprises an anti-CD8 VHH domain conjugated to a chelating moiety, wherein the chelating moiety chelates the VHH domain comprising 18 Complex of F label and aluminum. In some embodiments, the chelating moiety is a compound of formula (I).
[0166] In some embodiments, a CD8 binding agent is provided, which comprises a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated to any of the anti-CD8 VHH domains described herein.
[0167] In some embodiments, a CD8 binding agent is provided, which comprises a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated VHH domain, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 3.
[0168] In some embodiments, a CD8 binding agent is provided, which comprises a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated VHH domain, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the VHH domain comprises the amino acid sequence of SEQ ID NO: 4.
[0169] Exemplary contrast agents that can be used as detectable labels according to embodiments of the methods and compositions herein include, but are not limited to, barium, diatrizoate, ethiodized oil, gallium citrate, iocaic acid, iodoacetamide, iodoacetic acid, iodamide, iodoacetic acid, iodosac acid, iodociline, iohexyl, iobisulfate, iodopanic acid, iodocin, iodosifaric acid, iodosesilic acid, iodosulfone meglumine, iosemetic acid, iotasol, iodonic acid, iodonic acid, iodonic acid, iodonic acid, iodine ...
[0170] Bioluminescent and fluorescent compounds or molecules and dyes that can be used as detectable labels according to the methods and compositions herein include, but are not limited to, for example, fluorescein, fluorescein isothiocyanate (FITC), OREGON GREEN™, rhodamine, Texas Red, IRDye800CW, ALEXA FLUOR ® 647, tetrarhodamine isothiocyanate (TRITC), Cy3, Cy5, etc.), fluorescent markers (e.g., green fluorescent protein (GFP), phycoerythrin, etc.), autoquenched fluorescent compounds activated by tumor-associated proteases, enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, etc.), nanoparticles, biotin, digoxigenin, or a combination thereof.
[0171] Enzymes that can be used as detectable labels according to the methods and compositions herein include, but are not limited to, for example, horseradish peroxidase, alkaline phosphatase, acid phosphatase, glucose oxidase, β-galactosidase, β-glucoronidase or β-lactamase. Such enzymes can be used in combination with chromogens, fluorogenic compounds or luminogenic compounds to produce a detectable signal.
[0172] In some embodiments, the CD8 binding agents provided herein are conjugated to nanoparticles, that is, microscopic particles whose size is measured in nanometers. For example, nanoparticles are particles whose at least one dimension is less than about 100 nm. Nanoparticles can be used as detectable substances because they are small enough to scatter visible light rather than absorb it. For example, gold nanoparticles have significant visible light extinction properties and appear dark red to black in solution. Therefore, the CD8 binding agents provided herein that have been conjugated to nanoparticles can be used for imaging of in vivo T- cells in a subject. At the small end of the size range, nanoparticles are often referred to as clusters. Metallic, dielectric and semiconductor nanoparticles, as well as hybrid structures (e.g., core-shell nanoparticles) have been formed. Nanospheres, nanorods, and nanocups are just a few shapes that have been formed. Semiconductor quantum dots and nanocrystals are examples of additional types of nanoparticles. When conjugated to an anti-CD8 antibody (eg, anti-CD8 VHH) provided herein, such nanoscale particles can be used as imaging agents for in vivo T-cell detection as described herein.
[0173] Conjugates of antibodies and labels can be prepared using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionuclides to antibodies. See WO94 / 11026. The linker can be a "cleavable linker" that facilitates release of the cytotoxic drug in the cell. For example, an acid-labile linker, a peptidase-sensitive linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker can be used (Chari et al., 2001). Cancer Res.52:127-131 (1992); U.S. Pat. No. 5,208,020). The immunoconjugates herein include, but are not limited to, such conjugates prepared with cross-linking reagents, including but not limited to commercially available BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC and sulfo-SMPB and SVSB (succinimidyl-(4-vinylsulfone)benzoate) (e.g., from Pierce Biotechnology, Inc., Rockford, IL., USA). In some embodiments, the CD8 binding agents provided herein comprise a linker that is a deferoxamine compound (see, e.g., Vugts et al., (2017) Eur J Nucl Med Mol Imaging. 44:286-295 and Rudd et al. (2016) Chem Commun. 52: 11859-12000). In some embodiments, the CD8 binding agents provided herein comprise an N-succinyl-deferoxamine (DFO) linker. In some embodiments, the CD8 binding agents provided herein comprise a linker to a deferoxamine compound (e.g., N-succinyl-deferoxamine) and a radionuclide (e.g., including, but not limited to 89 Zr, 124 I or 18 F) Conjugated anti-CD8 VHH. In some embodiments, a label is conjugated to the anti-CD8 VHH domain in a site-specific manner, for example using an enzyme, such as sortase or transglutaminase.
[0174] In some embodiments, a CD8 binding agent provided herein comprises an anti-CD8 VHH domain directly coupled to a detectable label (ie, without a linker).
[0175] Methods for producing CD8 binding agents
[0176] Also provided herein are methods of producing the CD8 binding agents described herein, including methods of producing anti-CD8 antibodies (eg, anti-CD8 VHHs), and methods of producing labeled CD8 binding agents.
[0177] The anti-CD8 antibodies (e.g., anti-CD8 VHHs) described herein can be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 6,015,695. In some embodiments, isolated nucleic acids encoding anti-CD8 antibodies (e.g., anti-CD8 VHHs) described herein are described. Such nucleic acids can encode amino acid sequences comprising anti-CD8 VHH domains. In some embodiments, isolated nucleic acids encoding anti-CD8 VHH domains are provided, wherein the nucleic acid comprises a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a nucleic acid sequence encoding SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
[0178] In some embodiments, a vector (e.g., an expression vector) comprising a nucleic acid described herein is provided. In some embodiments, a host cell comprising such a nucleic acid or vector is provided. In some embodiments, the host cell is eukaryotic, for example, a Chinese hamster ovary (CHO) cell, an Expi293 cell, or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). In some embodiments, the host cell is prokaryotic, for example, an E. coli cell. In some embodiments, a method for preparing an anti-CD8 antibody (e.g., an anti-CD8 VHH) is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding an antibody as provided above under conditions suitable for expressing the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
[0179] Further provided is a method of preparing a labeled CD8 binding agent, comprising conjugating a chelating moiety to any of the anti-CD8 antibodies described herein (e.g., anti-CD8 VHHs) to provide a conjugate comprising the anti-CD8 antibody and the chelating moiety, and mixing the conjugate with a 18F to provide a labeled CD8 binder, wherein the chelating moiety is a compound of formula (I). In some embodiments, the chelating moiety is conjugated to a lysine residue of an anti-CD8 antibody. In some embodiments, the conjugate is contacted with an aluminum fluoride complex in the presence of one or more antioxidant compounds. In some embodiments, the one or more antioxidant compounds include methionine and / or N-acetyl-tryptophan. In some embodiments, the conjugate is contacted with an aluminum fluoride complex in the presence of methionine and N-acetyl-tryptophan. In some embodiments, the method includes purifying the labeled CD8 binder from a reaction mixture comprising the conjugate and aluminum fluoride through a desalting column. In some embodiments, the desalting column is equilibrated with a buffer comprising histidine, methionine, N-acetyltryptophan and / or sucrose. In some embodiments, the desalting column is equilibrated with a buffer comprising histidine, methionine, N-acetyltryptophan and sucrose.
[0180] For recombinant production of anti-CD8 antibodies (e.g., anti-CD8 VHHs), nucleic acid encoding the antibody is isolated, e.g., as described above, and inserted into a vector for further cloning and / or expression in a host cell. Such nucleic acid can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of specifically binding to genes encoding the heavy and light chains of the antibody).
[0181] Suitable host cells for cloning or expressing antibody-encoding vectors include the prokaryotic or eukaryotic cells described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not desired. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology , Volume 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing the expression of antibody fragments in E. coli). After expression, the antibodies can be isolated from the bacterial cell paste as a soluble fraction and can be further purified.
[0182] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized" to result in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004) and Li et al. Nat. Biotech. 24:210-215 (2006).
[0183] Suitable host cells for expression of glycosylated antibodies also come from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. A number of baculovirus strains have been identified that can be used with insect cells, particularly for use with Spodoptera frugiperda ( Spodoptera frugiperda ) cells for transfection.
[0184] Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TM technology).
[0185] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for growth in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol. 36:59 (1977); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary carcinoma (MMT 060562); TRI cells, as described, for example, in Mather et al., Annals NY Acad. Sci . 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR - CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980); and myeloma cell lines, such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology , Volume 248 (BKC Lo , Edit , Humana Press , Totowa ,NJ), pp. 255-268 (2003).
[0186] Detection, localization and / or imaging of CD8 using CD8 binding agents + Cell Methods
[0187] Provided herein are methods for detecting, localizing, and / or imaging CD8 using any of the CD8 binding agents described herein (e.g., an anti-CD8 antibody or an immunoconjugate comprising an anti-CD8 antibody and a detectable label). + Cells. In some embodiments, the method includes detecting the presence of CD8 in an in vitro or ex vivo sample. In some embodiments, the method includes adding a CD8 binding agent to an in vitro or ex vivo sample. Such methods include, but are not limited to, for example, protein blots, immunohistochemical analysis, EFISA assays, and the like, optionally including washing after adding the CD8 binding agent to the in vitro or ex vivo sample. In some embodiments, detecting the binding of the CD8 binding agent to CD8 includes detecting a label attached to an anti-CD8 VHH domain. In some embodiments, the method includes applying a second reagent comprising a detectable label of the present invention that binds to an anti-CD8:CD8 complex, and detecting the binding of the CD8 binding agent to CD8 includes detecting the detectable label of the second reagent. It will be readily understood by those of ordinary skill in the art that the second reagent does not compete with the CD8 binding agent for binding to CD8, or does not compete with CD8 for binding to the CD8 binding agent.
[0188] In some embodiments, the method includes detecting, locating or imaging the presence of CD8 in vivo. In some embodiments, the method includes administering a CD8 binding agent described herein to a subject. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal, for example, a rat, a mouse, a guinea pig, a hamster, a rabbit, a dog, a cat, a cow, a horse, a goat, a sheep, a donkey, a pig, a monkey, an ape or other non-human primate. In some embodiments, the non-human primate is a rhesus monkey or a cynomolgus monkey. In some embodiments, the CD8 binding agent is administered orally, topically or topically to the subject. In some embodiments, the CD8 binding agent is administered to the subject via an infusion (e.g., an intravenous infusion). In some embodiments, the infusion is intraperitoneal. In some embodiments, the CD8 binding agent is administered to the subject by injection, such as an intravenous injection or a subcutaneous injection. In some embodiments, the method includes administering a CD8 binding agent to the subject and removing a sample from the subject for analysis (i.e., detecting the binding of the CD8 binding agent to CD8).
[0189] In some embodiments, CD8 + Cells are detected, localized and / or imaged, e.g., using techniques described in further detail elsewhere herein.
[0190] In some embodiments, detecting the presence of CD8 in vivo comprises adding CD8 (e.g., CD8 + In some embodiments, the method includes determining the CD8 + In some embodiments, the subject has cancer, and detecting the presence of CD8 in vivo comprises converting CD8 + The cells are localized to the tumor. In some embodiments, CD8 + The cells are CD8 + T cells, e.g., tumor-infiltrating CD8 + In some embodiments, the method comprises determining the number of CD8 T cells in a tumor of a subject having cancer. + In some embodiments, the method comprises determining the number of CD8 T cells in a tumor of a subject having cancer at multiple consecutive time points. + The purpose of T cells.
[0191] In some embodiments, CD8 + Cells can be detected, localized or imaged in vivo within about 1 day or less after administration of the CD8 binding agent, such as within about 6 hours, 4 hours, 3 hours, 2 hours, 90 minutes, 1 hour, 30 minutes or less (e.g., about 30 minutes to about 6 hours, about 30 minutes to about 4 hours, or about 2 hours to 4 hours), including any values or ranges therebetween.
[0192] In some embodiments, any of the methods described herein can be used to detect, localize, or image CD8 in vivo without exceeding dosing guidelines. + Cells once or more, for example 1, 2, 3, 4, 5 times or more per year. In some embodiments, the method can be repeated about 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day or less after the first administration of the CD8 binding agent.
[0193] In some embodiments, the labeled CD8 binding agent can be used with one or more additional imaging agents for multiple imaging. In some embodiments, one or more additional imaging agents can be administered to the subject within a short period of time after administration of the labeled CD8 binding agent, for example, as soon as the radioactivity from the first imaging agent decreases, for example, within any of about 48 hours, 36 hours, 24 hours, 18 hours, 12 hours, 8 hours, 6 hours, 4 hours, 2 hours, 1 hour or less. In some embodiments, unlike long-lived imaging agents, the labeled CD8 binding agents described herein enable CD8 imaging to be combined with standard of care PET imaging (e.g., FDG-PET) or novel molecular imaging (e.g., CD4, granzyme B, PSMA) for additional characterization of immune responses. In some embodiments, the method further includes performing another imaging scan (e.g., PET, such as FDG-PET, SPECT or scintigraphy scan) within about 48 hours after imaging using the labeled CD8 binding agent.
[0194] In some embodiments, the methods can be used to detect, localize or image CD8 in vivo over an extended period of time. + Cells, for example, at least about 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any value or range between these values. The low immunogenicity of the CD8 binding agents described herein allows for repeated and prolonged use of CD8 binding agents for in vivo imaging and CD8 detection.
[0195] In some embodiments, the methods have a sensitivity of CD8 for in vivo CD8 detection of about 1 nM, 2 nM, 5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 40 nM, or 50 nM (e.g., at least about 50 nM, e.g., about 1 nM to about 50 nM or about 1 nM to about 30 nM), including any value or range between these values. In some embodiments, the methods have a linear correlation between the signal from the marker and the in vivo CD8 level. In some embodiments, the methods have a linear correlation between the signal from the marker and the in vivo CD8 level. In some embodiments, the methods have a linear correlation between the signal from the marker and the in vivo CD8 level in mouse CD8 + A tumor (e.g., TALL-1) xenograft model having a tumor:blood ratio of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20 or more.
[0196] Techniques for in vivo detection of CD8
[0197] In some embodiments, the CD8 binding agent binds to CD8 (e.g., CD8 + Cells, e.g., CD8 +In some embodiments, binding of a CD8 binding agent to CD8 is detected by at least one of immuno PET (positron emission tomography), SPECT (single photon emission computerized tomography), MRI (magnetic resonance imaging), which is also known as NMR (nuclear magnetic resonance), near infrared (NIR), or Cherenkov luminescence imaging (CLI). In some embodiments, binding of a CD8 binding agent to CD8 is detected by two or more forms of imaging. In some embodiments, binding of a CD8 binding agent to CD8 is detected by near infrared (NIR) and / or CLI. In some embodiments, binding of a CD8 binding agent to CD8 is detected by immunoSPECT and / or NIR fluorescence. In some embodiments, binding of a CD8 binding agent to CD8 is detected by immunoSPECT and computer tomography.
[0198] Immuno-PET is based on the use of positron-emitting radionuclides such as 18 F. 64 Cu, 68 Ga, 76 Br, 86 Y. 89 Zr and 124 I-labeled antibodies (such as anti-CD8 antibodies provided herein) or fragments thereof. Suitable radionuclides for labeling anti-CD8 antibodies include, but are not limited to, for example, 18 F. 64 Cu, 68 Ga, 76 Br, 86 Y. 88 Y. 89 Zr, 99m Tc, 111 In, 177 Lu, 123 I. 124 I. 125 I and 131 I. Depending on the starting positron energy and the density of the surrounding environment, the emitted positron will travel a distance of up to a few millimeters (see, e.g., Guus et al., (2007) The Oncologist, 12: 1379-1389 in Table 2). After having lost its kinetic energy, the positron combines with the electron, resulting in a so-called annihilation process, which produces two photons, each with an energy of 511 keV. The two photons are emitted simultaneously in opposite directions. The distribution of the positron-emitting radionuclide-labeled anti-CD8 antibody in the patient can be monitored by detecting the annihilation photon pairs with a PET camera. The PET camera consists of a circle of detectors placed around the patient's body. If two photons are recorded by detectors on the opposite side of the body within a very short time interval (typically 5-15 nanoseconds), it is assumed that an annihilation event has occurred somewhere along the line between the two detectors. By counting the intersections of all lines, the location of the radiation source (radiolabeled antibody) can be determined. For quantification, PET can provide reliable information when properly calibrated (see Verel et al., (2005) J Nucl Med, 46 Suppl 1: 164S-171S). Additional details about immunoPET are provided in, for example, van Dongen et al., (2007) The Oncologist, 12(12): 1379-1389; Reddy et al., (2010) Semin Nucl Med. 40(3): 182-189; Boerman et al., (2011) J. Nucl Med. 52(8): 1171-1172; Santangelo et al., (2015) Nature Methods, 12: 427-432.
[0199] ImmunoSPECT imaging requires administration of an antibody (e.g., an anti-CD8 antibody provided herein) or fragment thereof labeled with a gamma-emitting radionuclide to a subject, typically by injection into the bloodstream. Examples of gamma-emitting radionuclides include, but are not limited to, e.g., 67 Ga, 99m Tc, 111 In, 123 I. 131 I. 153 Sm or 186Re. Next, a gamma camera is used to acquire multiple 2-D images from multiple angles. A tomographic reconstruction algorithm is then applied to the multiple projections using a computer, resulting in a 3-D data set. The data set can then be manipulated to display thin slices along any selected axis of the body, similar to those obtained from other tomographic techniques. To acquire the SPECT images, the gamma camera is rotated around the patient. Projections are acquired at defined points during the rotation, generally every 3-6 degrees. In most cases, a full 360-degree rotation is used to obtain the best reconstruction. The time taken to acquire each projection is also variable, but is generally 15-20 seconds. This gives a total scan time of 15-20 minutes. In some cases, a SPECT gamma scanner can be made to operate in conjunction with a conventional CT scanner if the images are coregistration. This allows the location of tumors or tissues that can be seen on SPECT scintigraphy but are difficult to accurately locate relative to other anatomical structures. Additional details on immunoSPECT can be found, for example, in Laverman et al., (2015) J Nucl Med , 56(5): 778-783; Lutje et al., (2014) Cancer Res , 74(21): 6216-6223; Muselaers et al., (2013) Eur Urology 64(4): 1101-1106, etc.
[0200] The principle of in vivo MRI (magnetic resonance imaging), also known as NMR (nuclear magnetic resonance), is based on manipulating the magnetic properties of protons and neutrons (most commonly, those found in hydrogen atoms) contained in the nuclei of atoms present in the body of a subject. The movement of these nuclei produces small magnetic moments. When the subject's body is placed in the magnetic field of the MRI scanner, the magnetic moments of these nuclei align with the direction of the magnetic field. Radio frequency (RF) pulses are then applied to the subject's body in the scanner, which excites the nuclei so that there are transitions between lower and higher energy spin states. Once the RF pulses are given, the nuclei return to their equilibrium state (a process called relaxation), thereby releasing the extra energy they absorbed and emitting RF signals. The signals are detected by the RF coils of the scanner and are then used to generate detailed images of body tissues. By using MRI contrast agents, the contrast of the images and the visibility of specific body structures can be improved. Examples of markers detectable via MRI include, but are not limited to, for example, superparamagnetic iron oxide (including iron oxide nanoparticles, such as Molday ION Rhodamine-B Carboxyl), based on 19F probes, paramagnetic metals (e.g., gadolinium, manganese, manganese oxide, dysprosium), (U)SPIO, PARA (CEST), DIA (CEST), and PFCs. Additional information on the use of labeled antibodies for in vivo MRI and / or labels detectable via MRI is provided in, for example, Srivastava (2015). Dis Model Mech . 8(4): 323–336; Zhou et al., (2013) Wiley Interdiscip Rev Nanomed Nanobiotechnol. 5(1): 1–18; Sohn et al. (2015) Nanomedicine. 11(1): 127-135; Bates et al. (2014) PLoS ONE 9(5): e97220; discussed in Zhu et al., (2015) Int. J. Mol. Sci. 16: 9573-9587; and Zhang et al., (2014) Int J. Medicine. 9: 33-41.
[0201] NIR imaging utilizes deep photon penetration of near infrared light into living tissue to provide imaging of endogenous and / or exogenous controls at depths of <1 cm. Within the field, NIR fluorescence imaging focuses on detecting antibodies labeled with exogenous contrast agents that emit fluorescence at 700-900 nm. Typical fluorescence imaging systems have been described in detail elsewhere (De Grand et al., (2003)). Technol Cancer Res Treat , 2:553–62; Nakayama et al., (2002) Mol Imaging , 1:365–77; Ntziachristos et al., (2003) Radiol , 13:195–208; Tanaka et al., (2006) Ann Surg Oncol , 13:1671–81; Themelis et al., (2009) J Biomed Opt , 4:064012; and Troyan et al., (2009) Ann Surg Oncol , 16:2943–52. Briefly, it consists of a spectrally resolved light source (a filtered broadband source, a light emitting diode [LED], or a laser diode) that excites a fluorophore in a turbid medium. The light emitted from the fluorophore is then imaged onto a charge-coupled device (CCD) camera, with special care being taken to filter out the intense excitation light. Examples of infrared dyes include, but are not limited to, Tracy 652, Tracy 645, rhodamine dyes, cyanine dyes, Cy7, Cy7.5, ALEXA FLUOR ® ,CYDYE® 、IRDYE ® , DyLight and ATTO. Imaging of cells and tissues at near infrared (NIR) wavelengths of about 650 to about 950 nm is advantageous for in vivo imaging due to the low absorption of biomolecules in this region. Further details on the use of labeled antibodies for in vivo NIR imaging and detectable labels for in vivo NIR imaging are provided in Cillers et al., (2017) Mol Pharmaceuticals 14(5): 1623-1633; Hilderbrand et al. (2010) Curr Opin Chem Biol. 14(1): 71-79; Hong et al. (2017) Nat Biomed Eng. 1, 0010 DOI: 10.1038 / s41551-016-0010; Pansare et al. (2012) Chem Mater. 24(5): 812–827; Hickson (2009) Urol Oncol Semin Orig Invest. 27: 295-297; Zhang et al. (2012) Curr Protoc Cytom . Chapter 12: Unit 12.7; Quek et al., (2012) Nanomaterials. 2: 92-112; Luker et al., (2008) J Nucl Med 49:1-4; and Liu et al., (2016) NPG Asia Materials. 8, provided in e295.
[0202] Cherenkov luminescence imaging (CLI) is a molecular optical imaging technique based on the detection of optical Cherenkov photons emitted by positron emission tomography (PET) imaging agents such as those described elsewhere herein. Other CLI imaging agents include, but are not limited to, for example, 131 I. 18 F and 90 Y. Cherenkov radiation is produced when charged particles travel through a dielectric medium (i.e., a medium that can be polarized by an electric field) at a speed faster than the speed of light. While propagating, the charged particles (positively charged positrons or negatively charged electrons) induce local polarization by displacing the positive and negative charges of atoms in the medium. See, e.g., Grootendorst et al., (2016) Clin Transl Imaging. 4(5): 353-36). When the speed of the particle exceeds the speed of light, the polarization becomes asymmetric along the particle's path, resulting in a dipole electric field at greater distances from the particle. As the particle passes, the electrons of the atoms return to their ground state, emitting the transferred energy as optical photons. CLI images can be acquired by detecting the Cherenkov light from the PET tracer using an ultra-high sensitivity optical camera such as an electron multiplying charge coupled device (EMCCD) camera. CLI images can be analyzed semi-quantitatively as photon emission. CLI and PET are positively correlated because both techniques measure photons produced by positron-emitting radiopharmaceuticals; PET measures annihilation photons, while CLI measures Cherenkov photons. Several studies have shown strong correlations between CLI and PET for different radiopharmaceuticals in vitro, ex vivo, and in vivo, demonstrating the feasibility of CLI for molecular imaging in living subjects. Publications on CLI or detailing the correlation between CLI and PET include, for example, Xu et al., (2012) J Nucl Med , 53(2):312–317; Liu et al., (2010) PLoS ONE. 5(3):e9470; Zhang et al. (2013) PLoS ONE . 8(4):e62007; Hu et al., (2015) Eur Radiol. 25(6):1814–1822; Robertson et al. (2011) J Nucl Med. 52(11):1764–1769; Timmermand et al. (2015) J Nucl Med. 56(3):444–449; Cao et al. (2014) Biomed Opt Express. 5(10):3660–3670 and Thorek et al. (2014) J Nucl Med. 55(1):95–98.
[0203] Methods for predicting responsiveness of a subject with cancer to immunotherapy
[0204] Also provided are methods for predicting the responsiveness of a subject having cancer to treatment with an immunotherapeutic agent. In some embodiments, the method comprises administering a labeled CD8 binding agent and detecting the binding of the labeled CD8 binding agent to CD8 in a tumor tissue of the subject. + T cells, wherein detection of binding indicates that the subject is likely to respond to the immunotherapeutic agent. In some embodiments, the method comprises administering a labeled CD8 binding agent described herein and detecting binding of the labeled CD8 binding agent to CD8 in tumor tissue of the subject. +T cells, wherein detection of binding indicates that the subject is in need of treatment with an immunotherapeutic agent. In some embodiments, the CD8 binding agent is detectably labeled (e.g., 89 Zr, 124 I. 18 F. 68 Ga, etc.), and the labeled CD8 binding agent binds to CD8 in tumor tissue + The binding of T cells is detected via PET or PET / CT. In some embodiments, the CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is obtained by combining a compound of formula (I) with [ 18 F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0205] In some embodiments, the method comprises administering a therapeutically effective amount of an immunotherapeutic agent, a cell therapy, or a cancer vaccine (e.g., a personalized cancer vaccine or "PCV") to a subject in which a labeled CD8 binding agent has been detected to bind to CD8 in tumor tissue. + Binding of T cells.
[0206] In some embodiments, the CD8 binding agent is administered more than once for repeated prediction of the subject's responsiveness to the immunotherapeutic agent. In some embodiments, the method is repeated over an extended period of time, such as at least about 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any value or range between these values.
[0207] In some embodiments, the immunotherapeutic agent is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is a therapeutic anti-CTLA-4 antibody, such as ipilimumab (YERVOY®). In some embodiments, the immune checkpoint inhibitor is a therapeutic anti-PD-1 antibody. In some embodiments, the therapeutic anti-PD-1 antibody is nivolumab (OPDIVO®). In some embodiments, the therapeutic anti-PD-1 antibody is pembrolizumab (KEYTRUDA®). In some embodiments, the therapeutic anti-PD-1 antibody is pidlizumab.
[0208] In some embodiments, the immune checkpoint inhibitor is a therapeutic anti-PD-L1 antibody. In some embodiments, the therapeutic anti-PD-L1 antibody is BMS-936559. In some embodiments, the therapeutic anti-PD-L1 antibody is avelumab (BANVENCIO®). In some embodiments, the therapeutic anti-PD-L1 antibody is durvalumab (IMFINZI®). In some embodiments, the therapeutic anti-PD-L1 antibody is atezolizumab (TECENTRIQ®).
[0209] Further details on the therapeutic use of immune checkpoint inhibitors are provided in, for example, Byun et al., (2017) Nat Rev Endocrinol . 13: 195-207; La-Beck et al., (2015) Pharmacotherapy . 35(10): 963-976; Buchbinder et al., (2016) Am J Clin Oncol. 39(1): 98-106; Michot et al. (2016) Eur J Cancer. 54: 139-148 and Topalian et al., (2016) Nat Rev Cancer. 16: 275-287.
[0210] In some embodiments, the immune checkpoint inhibitor is administered to a subject in combination with one or more additional therapeutic (e.g., chemotherapeutic) agents. In some embodiments, the immune checkpoint inhibitor administered to a subject in combination with one or more additional therapeutic (e.g., chemotherapeutic) agents is an anti-PD-L1 antibody (e.g., atezolizumab). Examples of chemotherapeutic agents include erlotinib (TARCEVA ®, Genentech / OSI Pharm.), bortezomib (VELCADE®, Millennium Pharm.), disulfiram, epigallocatechin gallate, salinosporamide A, carfilzomib, 17-AAG (geldanamycin), radicicol, lactate dehydrogenase A (LDH-A), fulvestrant (FASLODEX ® , AstraZeneca), sunitinib (SUTENT®, Pfizer / Sugen), letrozole (FEMARA ® , Novartis), imatinib mesylate (GLEEVEC ® ,Novartis),finasunate(VATALANIB ® , Novartis, oxaliplatin (ELOXATIN ® , Sanofi), 5-FU (5-fluorouracil), folinic acid, rapamycin (sirolimus, RAPAMUNE ® , Wyeth, Lapatinib (TYKERB ® , GSK572016, Glaxo Smith Kline), Lonafamib (SCH 66336), sorafenib (NEXAVAR®, Bayer Labs), gefitinib (IRESSA ® , AstraZeneca), AG1478, alkylating agents such as thiotepa and CYTOXAN ®Cyclophosphamide; alkyl sulfonates such as busulfan, dipropylamine sulfonate and piposulfan; aziridines such as benzodopa, carboquinone, meturedopa and uredopa; ethyleneimines and methylamelamines including hexamethylmelamine, triethylenemelamine, triethylenephosphamide, ethophosphothion and trimethylolmelamine; acetogenins (especially bullatacin and bullatacinone); camptothecins (including topotecan and irinotecan); bryostatin; callystatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin and bizelesin); cryptophycins (especially cryptophycin 1 and cryptophycin8); adrenal steroids (including prednisone and prednisolone); cyproterone acetate; 5α-reductase inhibitors (including finasteride and dutelite); vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat, dolastatin; aladiuzin, talcum duocarcin (including synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sa raccodictyin); spongistatin; nitrogen mustards, for example, chlorambucil, chlomaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, oxazolidinone hydrochloride, melphalan, neomuscarin, phenambucil, chlorambucil, cyclophosphamide, uracil mustard; nitrosoureas, for example, carmustine, chlorozotocin, fortamustine, lomustine, nimodipine and renomustine; antibiotics, for example, enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma 1I and calicheamicin omega 1I ( Angew Chem. Intl. Ed. Engl.1994, 33:183-186); dynemicins, including dynemicin A; bisphosphonates, such as clodronate disodium; esperamicins; and the neocarcinogens and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycins, authramycins, azaserine, bleomycins, cactinomycins, carabicin, caminomycins, chromomycins, actinomycin D, daunorubicin, diethoxyacetyl doxorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN ® (doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, didoxorubicin, idarubicin, mexicomycin, mitomycins such as mitomycin C, mycophenolic acid, nogaramycin, olivomycin, peloton, porfiromycin, puromycin, triferric doxorubicin, rodorubicin, streptozotocin, streptozotocin, tuberculocidin, ubenimex, neocarzinostatin, doxycycline; antimetabolites such as methotrexate and 5-fluorouracil 5-FU; folic acid analogs such as dimethoate, methotrexate, pteroyltriglutamate, trimesate; purine analogs such as fludarabine, 6-mercaptopurine, azathioguanine, thioguanine; pyrimidine analogs such as cyclocytidine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, docefluridine, enoxabin, floxuridine; androgens such as calutosterone, hydroxymethylandrosterone propionate, cyclothiodine, methylthiocyclostane, testolactone; antiadreners such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as frolinic acid; acetylglucosyl ester; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisacrine; edatrexate; defofamine; colcemid; diazocone; elfomithine; hydroxypicrotoxin acetate; epothilone; glycidyl ether; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansine alkaloids, such as maytansine and maytansine; chlorambucil; mitoxantrone; mopidamnol; nitraerine; pentostatin; belemide; pirarubicin; losoxantrone; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK ®polysaccharide complex (JHS NaturalProducts, Eugene, Oreg.); azoxystrobin; rhizoxin; schizophyllan; spirogermanium; tricrosporin; triamcinolone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, baculocin A, and anguidine); urethane; vindesine; dacarbazine; mannitol mustard; dibromomannitol; dibromodulanol; piperobroman; gacytosine; cytarabine ("Ara-C"); cyclophosphamide; thiotepa; taxoids, for example, TAXOL (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE ® (without Cremophor), albumin-engineered paclitaxel nanoparticles (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE ® (docetaxel; Sanofi-Aventis); chlorambucil; GEMZAR ® (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE ® (vinorelbine); dihydroxyanthraquinone; teniposide; edatrexate; daunorubicin; aminopterin; capecitabine (XELODA ® ); ibandronate sodium; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the foregoing.
[0211] Chemotherapeutic agents also include (i) antihormonal agents that act to modulate or inhibit hormonal effects on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX ® ; tamoxifen citrate), raloxifene, droloxifene, iodoxyfene, 4-hydroxytamoxifen, treoxifene, naloxifene, LY117018, onasone, and FARESTON ® (toremifene citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazole, aminoglutethimide, MEGASE® (Megestrol acetate), AROMASIN ® (exemestane; Pfizer), formestanie, fadrozole, RIVISOR ® (vorozole), FEMARA ® (letrozole; Novartis) and ARIMIDEX ® (anastrozole; AstraZeneca); (iii) antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprorelin, and serotonin; buserelin, triptorelin, medroxyprogesterone acetate, diethylstilbestrol, premarin, fluoxymesterone, all-trans retinoic acid, retinamide, and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those that inhibit the expression of genes in signaling pathways involved in abnormal cell proliferation, such as, for example, PKC-α, Ralf, and H-Ras; (vii) ribozymes, such as inhibitors of VEGF expression (e.g., ANGIOZYME ® ) and HER2 expression inhibitors; (viii) vaccines, such as gene therapy vaccines, such as ALLOVECTIN ® LEUVECTIN ® and VAXID ® ;PROLEUKIN ® , rIL-2; topoisomerase 1 inhibitors, such as LURTOTECAN ® ;ABARELIX ® rmRH; and (ix) pharmaceutically acceptable salts, acids and derivatives of any of the foregoing.
[0212] Chemotherapeutic agents also include antibodies such as alemtuzumab (Campath), bevacizumab (AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech / Biogen Idec), pertuzumab (OMNITARG®, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), tositumomab (Bexxar, Corixia) and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth). Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the present application include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, Fontolizumab, gemtuzumab ozogamicin, inotuzumabozogamicin), ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pacolizumab pascolizumab, pecfusituzumab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan), tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab, and anti-interleukin-12 (ABT-874 / J695, Wyeth Research and Abbott Laboratories), which is a recombinant fully human sequence, full-length IgG genetically modified to recognize the interleukin-12 p40 protein 1 Lambda antibody.
[0213] Chemotherapeutic agents also include "EGFR inhibitors," which refer to compounds that bind to or otherwise directly interact with EGFR and prevent or reduce its signaling activity, and on the other hand are referred to as "EGFR antagonists." Examples of such agents include antibodies and small molecules that bind to EGFR. Examples of antibodies that bind to EGFR include MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509) (see U.S. Pat. No. 4,943,533, Mendelsohn et al.) and variants thereof, such as chimeric 225 (C225 or cetuximab; ERBUTIX ® ) and remodeled human 225 (H225) (see WO 96 / 40210, Imclone Systems Inc.); IMC-11F8, a fully human antibody targeting EGFR (Imclone); antibodies that bind to type II mutant EGFR (U.S. Pat. No. 5,212,290); humanized and chimeric antibodies that bind to EGFR as described in U.S. Pat. No. 5,891,996; and human antibodies that bind to EGFR, such as ABX-EGF or panitumumab (see WO 98 / 50433, Abgenix / Amgen); EMD 55900 (Stragliotto et al., Eur. J. Cancer 32A:636-640 (1996); EMD7200 (matuzumab), a humanized EGFR antibody to EGFR that competes with both EGF and TGF-α for EGFR binding (EMD / Merck); a human EGFR antibody, HuMax-EGFR (GenMab); fully human antibodies designated E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3, and E7.6.3 and described in US 6,235,883; MDX-447 (Medarex Inc); and mAb 806 or humanized mAb 806 (Johns et al., J. Biol. Chem. 279(29):30375-30384 (2004)). Anti-EGFR antibodies can be conjugated with cytotoxic agents to produce immunoconjugates (see, for example, EP659439A2, Merck Patent GmbH). EGFR antagonists include small molecules, such as those described in U.S. Patent Nos. 5,616,582; 5,457,105; 5,475,001; 5,654,307; 5,679,683; 6,084,095; 6,265,410; 6,455,534; 6,521,620; 6,596,726; 6,713,484; 5,770,599; 6,140,332; 5,866,572; 6,399,602; 6,344,459; 6,602,863; 6,391,874; 6,344,455; 5,760,041; 6,002,008; and 5,747,498; and the following PCT publications: WO 98 / 14451, WO 98 / 50038, WO 99 / 09016 and WO 99 / 24037. Specific small molecule EGFR antagonists include OSI-774 (CP-358774, erlotinib, TARCEVA ®Genentech / OSI Pharmaceuticals); PD 183805 (CI 1033, 2-acrylamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholino)propoxy]-6-quinazolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA®) 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166 ((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol); (R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine); CL-387785 (N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide); EKB-569 (N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); AG1571 (SU 5271; Pfizer); dual EGFR / HER2 tyrosine kinase inhibitors such as lapatinib (TYKERB®, GSK572016 or N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6[5[[[2-methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-aminoquinazoline).
[0214] Chemotherapeutic agents also include "tyrosine kinase inhibitors", including the EGFR-targeted drugs mentioned in the previous paragraph; small molecule HER2 tyrosine kinase inhibitors such as TAK165, available from Takeda; CP-724, 714, oral selective inhibitors of ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual-HER inhibitors such as EKB-569 (available from Wyeth), which preferentially binds to EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib (GSK572016; available from Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis); pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as those available from ISIS Pharmaceuticals, which inhibits Raf-1 signaling; non-HER targeted TK inhibitors, such as imatinib mesylate (GLEEVEC®, available from Glaxo SmithKline); multi-targeted tyrosine kinase inhibitors, such as sunitinib (SUTENT®, available from Pfizer); VEGF receptor tyrosine kinase inhibitors, such as vatalanib (PTK787 / ZK222584, available from Novartis / Schering AG); MAPK extracellular regulated kinase I inhibitor CI-1040 (available from Pharmacia); quinazolines, such as PD153035, 4-(3-chloroanilino)quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines, such as CGP 59326, CGP 60261, and CGP 62706; pyrazolopyrimidine, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine; curcumin (diferuloylmethane, 4,5-bis(4-fluoroanilino)phthalimide); tyrosine phosphorylation inhibitors containing a nitrothiophene moiety; PD-0183805 (Warner-Lambert); antisense molecules (e.g., those that bind to the acid encoding HER); quinoxalines (U.S. Pat. No. 5,804,396); tryphostins (U.S. Pat. No.5,804,396); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG); pan-HER inhibitors, such as CI-1033 (Pfizer); Affinitac (ISIS 3521; Isis / Lilly); imatinib mesylate (GLEEVEC®); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG); INC-1C11 (Imclone), rapamycin (sirolimus, RAPAMUNE®); or as disclosed in any of the following patents: U.S. Patent No. 5,804,396; WO 1999 / 09016 (American Cyanamid); WO 1998 / 43960 (American Cyanamid); WO1997 / 38983 (Warner Lambert); WO 1999 / 06378 (Warner Lambert); WO 1999 / 06396 (WarnerLambert); WO 1996 / 30347 (Pfizer, Inc); WO 1996 / 33978 (Zeneca); WO 1996 / 3397 (Zeneca) and WO 1996 / 33980 (Zeneca). .
[0215] Chemotherapeutic agents also include dexamethasone, interferon, colchicine, chlorpheniramine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG active, bevacizumab, bexarotene, cladribine, clofarabine, darbepoetin alfa, and dapoxetine. alfa), denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, cistulaline acetate, ibritumomab, interferon alfa-2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxypsoralen, nandrolone, nelarabine, nofetumomab, oprelvekin, palifermin, pamidronate, pegademase, pegfilgrastim, pemetrexed disodium), plicamycin, porfimer sodium, mipaclin, rasburicase, sargramostim, temozolomide, VM-26, 6-TG, toremifene, tretinoin, ATRA, valrubicin, zoledronate and zoledronic acid, and pharmaceutically acceptable salts thereof.
[0216] Chemotherapeutic agents also include hydrocortisone, hydrocortisone acetate, cortisone acetate, thiocortisone pivalate, triamcinolone acetonide, triamcinolone, mometasone, amcinolone acetonide, budesonide, hydroxyprednisolone, fluocinolone acetonide, fluocinolone acetate, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicasone, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, and flumethasone acetate; immunoselective anti-inflammatory peptides (ImSAIDs), such as phenylalanine-glutamine-glycine (FEG) and its D-isomer (feG) (IMULAN BioTherapeutics, LLC); antirheumatic drugs such as azathioprine, cyclosporine (CsA), D-penicillamine, gold salts, hydroxychloroquine, leflunomide, sulfasalazine, tumor necrosis factor alpha (TNFα) blockers such as etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab (Certolizumab) pegol) (Cimzia), golimumab (Simponi), interleukin 1 (IL-1) blockers such as anakinra (Kineret), T cell costimulation blockers such as abatacept (Orencia), interleukin 6 (IL-6) blockers such as tocilizumab (ACTEMERA®); interleukin 13 (IL-13) blockers such as lebrikizumab; interferon alpha (IFN) blockers such as rontalizumab; β7 integrin blockers such as rhuMAb β7; IgE pathway blockers such as anti-M1'; secreted homotrimeric LTa3 and membrane-bound heterotrimeric LTa1 / β2 blockers such as anti-lymphotoxin α (LTa); radioisotopes (e.g., At 211 ,I 131 ,I 125 , Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 , P 32 , Pb 212and radioisotopes of Lu); various research reagents, such as thioplatin, PS-341, phenyl butyrate, ET-18- OCH 3 or farnesyltransferase inhibitors (L-739749, L-744832); polyphenols such as quercetin, resveratrol, piceatannol, epigallocatechin gallate, theaflavins, flavanols, procyanidins, betulinic acid and its derivatives; autophagy inhibitors such as chloroquine; delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicine; betulinic acid; acetylcamptothecin, scopolectin, and 9-aminocamptothecin; podophyllotoxin; flurbiprofen (UFTORAL®); bexarotene (TARGRETIN®); bisphosphonates such as clodronate disodium (e.g., BONE FOS® or OSTAC®), etidronate (DIDROCAL®), NE-58095, zoledronic acid / zoledronate (ZOMETA®), alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®), or risedronate (ACTONEL®); and epidermal growth factor receptor (EGF-R); vaccines, such as THERATOPE® vaccine; perifosine, COX-2 inhibitors (such as celecoxib or etoricoxib), proteosome inhibitors (such as PS341); CCI-779; tipifarnib (R11577); orafenib, ABT510; Bcl-2 inhibitors, such as oblimersen sodium) (GENASENSE®); pixantrone; farnesyltransferase inhibitors, such as lonafarnib (SCH 6636, SARASAR TM ); and a pharmaceutically acceptable salt, acid or derivative of any of the above; and combinations of two or more of the above, such as CHOP, an abbreviation for cyclophosphamide, doxorubicin, vincristine and prednisolone combination therapy; and FOLFOX, an abbreviation for oxaliplatin combined with 5-FU and folinic acid (ELOXATIN TM ) is an abbreviation for the treatment regimen.
[0217] Chemotherapeutic agents also include nonsteroidal anti-inflammatory drugs with analgesic, antipyretic and anti-inflammatory effects. NSAIDs include non-selective inhibitors of the enzyme cyclooxygenase. Specific examples of NSAIDs include aspirin, propionic acid derivatives such as ibuprofen, fenoprofen calcium, ketoprofen, flurbiprofen, oxaprozin and naproxen, acetic acid derivatives such as indomethacin, sulindac, etodolac, diclofenac sodium, enolic acid derivatives such as piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam, fenamic acid derivatives such as mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, and COX-2 inhibitors such as celecoxib, etoricoxib, lumiracoxib, parecoxib, rofenoxib, rofenoxib and valdecoxib.
[0218] In some embodiments, an anti-PD-L1 antibody (e.g., atezolizumab) is administered in combination with one or more of the following chemotherapeutic agents: an anti-HER2 antibody (e.g., trastuzumab (HERCEPTIN®, Genentech) or pertuzumab (PERJETA®, Genentech)), a PD1 binding antagonist (e.g., MDX-1106 (nivolumab), MK-3475 (pembrolizumab, lambrolizumab), CT-011 (pidilizumab), or AMP-224), and a PD-L2 binding antagonist.
[0219] In some embodiments, an anti-PD-L1 antibody (e.g., atezolizumab) is administered in combination with a growth inhibitor. As used herein, a "growth inhibitor" refers to a compound or composition that inhibits cell growth in vitro or in vivo. Exemplary growth inhibitors include, for example, vincas (vincristine and vinblastine), taxanes (docetaxel (TAXOTERE®, Rhone-Poulenc Rorer) and paclitaxel (TAXOL®, Bristol-Myers Squibb)) and topoisomerase II inhibitors, such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over to S-phase arrest, such as DNA alkylating agents, such as tamoxifen, prednisone, dacarbazine, nitrogen mustard, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in Mendelsohn and Israel, eds., The Molecular Basis of Cancer, Chapter 1, Murakami et al., entitled “Cell cycle regulation, oncogenes, and antineoplastic drugs” (WB Saunders, Philadelphia, 1995), e.g., page 13.
[0220] In some embodiments, the immunotherapeutic agent is a dendritic cell activator or a dendritic cell growth factor. In some embodiments, the immunotherapeutic agent is a vaccine adjuvant. In some embodiments, the immunotherapeutic agent is a T-cell stimulator or a growth factor. In some embodiments, the immunotherapeutic agent is an agent that neutralizes or inhibits suppressive immune cells, cytokines, and / or enzymes.
[0221] In some embodiments, the method comprises administering an immunotherapeutic selected from the group consisting of an anti-TIGIT antibody, a TIGIT antagonist, an anti-CSF-1R antibody, an anti-CSF-1R antagonist, an anti-CEA antibody, an anti-CEA antagonist, an anti-CTLA4 antibody, a CTLA4 antagonist, an anti-OX40 antibody, an OX40 agonist, any anti-PDL1 antibody in combination with one or more chemotherapeutic agents, any anti-PD1 antibody in combination with one or more chemotherapeutic agents, and atezolizumab in combination with one or more chemotherapeutic agents. In some embodiments, an anti-PD1 or anti-PDL1 antibody is administered with TARCEVA ® (erlotinib), ZELBORAF ® (Vemurafenib), GAZYVA ® (Atozumab), AVASTIN ® (bevacizumab), COTELLIC ®(cobimetinib), ZELBORAF ® (Vemurafenib) and COTELLIC ® (cobimetinib), ALECENSA ® (Alectinib), KADCYLA ® (trastuzumab emtansine conjugate), HERCEPTIN ® (trastuzumab), PERJETA ® (pertuzumab), polotuzumab, INF-α, an anti-CD40 agent, an anti-OX40 antibody (e.g., an OX40 agonist), an anti-CSF-1R antibody, an anti-CEA antibody, an IDO inhibitor, or an anti-TIGIT antibody. In some embodiments, the anti-PD-L1 antibody is atezolizumab, and atezolizumab is combined with TARCEVA ® (erlotinib), ZELBORAF ® (Vemurafenib), GAZYVA ® (Atozumab), AVASTIN ® (bevacizumab), COTELLIC ® (cobimetinib), ZELBORAF ® (Vemurafenib) and COTELLIC ® (cobimetinib), ALECENSA ® (Alectinib), KADCYLA ® (trastuzumab emtansine conjugate), HERCEPTIN ® (trastuzumab), PERJETA ® (pertuzumab), polotuzumab, INF-α, anti-CD40 agent, anti-OX40 antibody (e.g., OX40 agonist), anti-CSF-1R antibody, anti-CEA antibody, IDO inhibitor, anti-CTLA4 antibody or anti-TIGIT antibody. In some embodiments, the immunotherapeutic agent is a cytokine. In some embodiments, the cytokine is IL2, artificially modified IL2, IL15 or artificially modified IL15. In some embodiments, the immunotherapeutic agent is a dendritic cell modulator, such as a dendritic cell activator or a dendritic cell growth factor.
[0222] In some embodiments, the cell therapy is a chimeric antigen receptor T cell (CAR-T) therapy. In some embodiments, the cell therapy is an engineered T-cell receptor T cell (TCR-T) therapy. In some embodiments, the cell therapy is a neoantigen-specific T cell therapy.
[0223] Method of monitoring progression in a subject suffering from cancer
[0224] Provided herein are methods for monitoring disease progression in a subject suffering from cancer. The method comprises administering a labeled CD8 binding agent to the subject and detecting the binding of the labeled CD8 binding agent to CD8 in a tumor tissue of the subject at a first time point and a second time point. + In some embodiments, the method further comprises administering to the subject a therapeutically effective amount of an immunotherapeutic agent (e.g., an immunotherapeutic agent described elsewhere herein), wherein the disease has progressed in the subject. In some embodiments, the method comprises (a) administering to the subject a labeled CD8 binding agent prior to administering the immunotherapeutic agent and detecting the binding of the labeled CD8 binding agent to CD8 in the tumor tissue. + (a) administering an immunotherapeutic agent, and (c) administering a labeled CD8 binding agent to a subject at a time point after the administration of the immunotherapeutic agent and detecting the binding of the labeled CD8 binding agent to CD8 in the tumor tissue. + T cells, and (d) measuring CD8 + Differences in T cell markers.
[0225] In some embodiments, the immunotherapeutic agent is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is an anti-PD1 antibody (e.g., but not limited to, an anti-PD1 antibody described herein). In some embodiments, the immune checkpoint inhibitor is an anti-PD-L1 antibody (e.g., but not limited to, an anti-PD-L1 antibody described herein). In some embodiments, the anti-PD-L1 antibody is atezolizumab. In some embodiments, an anti-PD-L1 antibody (e.g., atezolizumab) is administered to a subject in combination with a second therapeutic agent (e.g., but not limited to, an immunotherapeutic agent and / or a chemotherapeutic agent described elsewhere herein). In some embodiments, the second therapeutic agent is an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is an anti-PD-L1 antibody or an anti-PD1 antibody, which is further combined with an anti-TIGIT antibody, a TIGIT antagonist, an anti-CSF-1R antibody, an anti-CSF-1R antagonist, an anti-CEA antibody, an anti-CEA antagonist, an anti-OX40 antibody, an OX40 agonist, an anti-CTLA4 antibody, a CTLA4 antagonist, TARCEVA ® (erlotinib), ZELBORAF ® (Vemurafenib), GAZYVA ® (Atozumab), AVASTIN ® (bevacizumab), COTELLIC ® (cobimetinib), ZELBORAF ® (Vemurafenib) and COTELLIC ® (cobimetinib), ALECENSA® (Alectinib), KADCYLA ® (trastuzumab emtansine conjugate), HERCEPTIN ® (trastuzumab), PERJETA ® (pertuzumab), polotuzumab, INF-α, anti-CD40 agents, or an IDO inhibitor.
[0226] In some embodiments, the immunotherapeutic agent is a cytokine. In some embodiments, the cytokine is IL2, artificially modified IL2, IL15, or artificially modified IL15.
[0227] In some embodiments, the immunotherapeutic agent is a dendritic cell modulator. In some embodiments, the immunotherapeutic agent is a dendritic cell activator or a dendritic cell growth factor.
[0228] In some embodiments, the effect of the immunotherapeutic agent is determined by measuring CD8 + T cells and compared them with the CD8 + In some embodiments, when the number of CD8 T cells in the tumor tissue at the second time point is greater than that in the tumor tissue at the second time point, the number of CD8 T cells in the tumor tissue at the second time point is greater than that in the tumor tissue at the second time point. + The level of T cells was higher than that of CD8 T cells in tumor tissue at the first time point. + In some embodiments, the level of CD8 T cells in tumor tissue is detected at a third, fourth, or fifth later time point. + In some embodiments, the time points are at least 1 day, 3 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 12 months, 1.5 years, 2 years, 2.5 years, 3 years, or more than 3 years apart. In some embodiments, CD8 T cells are detected in tumor tissue after the immunotherapeutic agent is administered to the patient. + T cell levels.
[0229] In some embodiments, the effect of one or more dosing regimens of an immunotherapeutic agent on tumor tissue is determined by comparing CD8 in the patient's tumor tissue at a first time point and at a second time point as measured by a CD8 binding agent. + In some embodiments, the level (or localization) of CD8+ T cells in tumor tissue after administration of an immunotherapeutic agent to a subject is determined by comparing the level of CD8+ T cells in the tumor tissue measured by a CD8 binding agent at a first time point before administration of the immunotherapeutic agent and at a second time point after administration. + The level of T cells was determined.
[0230] In some embodiments, the CD8 binding agent is detectably labeled (e.g., 89 Zr, 124 I. 18 F. 68 Ga, etc.), and the labeled CD8 binding agent is detected by PET or PET / CT to bind to CD8 in tumor tissue. + In some embodiments, the CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0231] In some embodiments, more than one administration of a CD8 binding agent is used to repeatedly monitor cancer progression in a subject. In some embodiments, a subject is monitored over an extended period of time, such as at least about 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any values or ranges between these values.
[0232] Method of monitoring the progress of treatment in a subject suffering from cancer
[0233] Provided herein are methods for monitoring the progress of treatment in a subject having cancer who has previously received or is currently receiving treatment with an immunotherapeutic agent (e.g., an immunotherapeutic agent described elsewhere herein). The method comprises administering a labeled CD8 binding agent to the subject along with the immunotherapeutic agent, and detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue at a first time point and a second time point. +In some embodiments, the labeled CD8 binding agent is administered before the immunotherapeutic agent, and the first time point is after administration of the labeled CD8 binding agent and before administration of the immunotherapeutic agent, and the second time point is after administration of the immunotherapeutic agent. In some embodiments, a lower level of CD8 in the tumor tissue at the second time point compared to the first time point + T cells indicate positive treatment progress (e.g., beneficial or desired clinical outcome). In some embodiments, higher levels of CD8 T cells in tumor tissue at the second time point compared to the first time point. + T cells indicate a lack of treatment progress (e.g., a lack of beneficial or desired clinical outcome). In some embodiments, the immunotherapeutic agent is administered before the labeled CD8 binding agent, the first time point is after administration of the immunotherapeutic agent and after administration of the labeled CD8 binding agent, and the second time point is after the first time point. In some embodiments, a lower level of CD8 in the tumor tissue at the second time point compared to the first time point + T cells indicate positive treatment progress (e.g., beneficial or desired clinical outcome). In some embodiments, higher levels of CD8 T cells in tumor tissue at the second time point compared to the first time point + T cells indicate a lack of treatment progress (e.g., a lack of beneficial or desired clinical outcome). In some embodiments, the methods are used to explain the mechanism of treatment failure, for example, by tumor CD8 + In some embodiments, CD8 T cells are detected in tumor tissue at a third, fourth, or fifth subsequent time point. + In some embodiments, the time points are at least about 1 day, 3 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 12 months, 1.5 years, 2 years, 2.5 years, 3 years, or more than three years apart.
[0234] In some embodiments, the immunotherapeutic agent is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is an anti-PD-L1 antibody (e.g., as described elsewhere herein). In some embodiments, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-L1 antibody (e.g., atezolizumab) is administered to a subject in combination with a second therapeutic agent (e.g., as described elsewhere herein).
[0235] In some embodiments, the CD8 binding agent is detectably labeled (e.g., 89 Zr, 124 I. 18 F. 68Ga, etc.), and the labeled CD8 binding agent is detected by PET or PET / CT to bind to CD8 in tumor tissue. + In some embodiments, the CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0236] In some embodiments, more than one administration of a CD8 binding agent is used to repeatedly monitor the progress of treatment in a subject. In some embodiments, a subject is monitored over an extended period of time, e.g., at least about 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any values or ranges between these values.
[0237] Methods for predicting the responsiveness of a subject having cancer to treatment with a cancer vaccine and monitoring the efficacy of a subject having cancer Methods of vaccines for disease progression in subjects suffering from cancer
[0238] Provided herein are methods for predicting the responsiveness of a subject having cancer to treatment with a cancer vaccine. In some embodiments, the cancer vaccine is a personalized cancer vaccine ("PCV"). Exemplary PCVs are described, for example, in Ott et al., (2017) Nature 547, 217-221 and Sahin et al., (2017) Nature In some embodiments, the method comprises administering a labeled CD8 binding agent as described herein and detecting binding of the labeled CD8 binding agent to CD8 in tumor tissue in the subject. + T cells, wherein the detection of said binding indicates that the subject is likely to respond to the cancer vaccine. In some embodiments, the method comprises administering a labeled CD8 binding agent as described herein and detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue in the subject. +The binding of a cancer vaccine to a T cell, wherein the detection of the binding indicates that the subject is in need of treatment with a cancer vaccine. In some embodiments, the cancer vaccine is administered in combination with one or more immunotherapeutic agents and / or chemotherapeutic agents described herein.
[0239] Also provided herein is a method for monitoring disease progression in a subject suffering from cancer. The method comprises administering a CD8 binding agent described herein to the subject and detecting the presence of a labeled CD8 binding agent and CD8 in a tumor tissue in the subject at a first time point and a second time point. + In some embodiments, the method further comprises administering a therapeutically effective amount of a cancer vaccine. In some embodiments, the cancer vaccine is a personalized cancer vaccine ("PCV").
[0240] Provided herein are methods for monitoring treatment progress in a subject with cancer who has previously received or is currently receiving treatment with a cancer vaccine. In some embodiments, the cancer vaccine is a personalized cancer vaccine ("PCV"). In some embodiments, the method comprises (a) prior to administering the cancer vaccine (e.g., PCV), administering to the subject a labeled CD8 binding agent and detecting binding of the labeled CD8 binding agent to CD8 in tumor tissue. + (a) administering a cancer vaccine (e.g., PCV) to a subject, and (b) administering a labeled CD8 binding agent to a subject at a time point after administration of the cancer vaccine (e.g., PCV) and detecting binding of the labeled CD8 binding agent to CD8 in tumor tissue. + T cells, and (d) measuring CD8 + In some embodiments, the methods are used to explain the mechanism of treatment failure, for example, by tumor CD8 + Loss of cells, by exhaustion and / or by loss of therapeutic potential.
[0241] In some embodiments, the CD8 binding agent is detectably labeled (e.g., 89 Zr, 124 I. 18 F. 68 Ga, etc.), and the labeled CD8 binding agent is detected by PET or PET / CT to bind to CD8 in tumor tissue. + In some embodiments, the CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is a compound of formula (I) and [ 18F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0242] In some embodiments, more than one administration of a CD8 binding agent is used for repeated prediction or monitoring in a subject. In some embodiments, the method or monitoring subject is repeated over an extended period of time, such as at least about 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any value or range between these values.
[0243] Methods for predicting the responsiveness of a subject having cancer to treatment with cell therapy and monitoring the efficacy of a subject having cancer Methods of treating disease progression in a subject suffering from cancer
[0244] Provided herein are methods for predicting the responsiveness of a subject with cancer to treatment with a cell therapy. In some embodiments, the cell therapy is a CAR-T or a neoantigen-specific T cell therapy. Exemplary cell therapies are described, for example, in June et al., (2018) Science 359, 1361-1365 and Guedan et al., (2019) Annu. Rev. Immunol. In some embodiments, the method comprises administering a labeled CD8 binding agent described herein and detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue in the subject. + T cells, wherein the detection of said binding indicates that the subject is likely to respond to the cell therapy. In some embodiments, the method comprises administering a labeled CD8 binding agent as described herein and detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue in the subject. + T cells, wherein detection of said binding indicates that the subject is in need of treatment with the cell therapy. In some embodiments, the cell therapy is administered in combination with one or more immunotherapeutic agents and / or chemotherapeutic agents described herein.
[0245] Also provided herein is a method for monitoring disease progression in a subject suffering from cancer. The method comprises administering a CD8 binding agent described herein to the subject and detecting the presence of a labeled CD8 binding agent and CD8 in a tumor tissue in the subject at a first time point and a second time point. + In some embodiments, the method further comprises administering a therapeutically effective amount of a cell therapy.
[0246] Provided herein are methods for monitoring treatment progress in a subject with cancer who has previously received or is currently receiving treatment with a cell therapy. In some embodiments, the cell therapy is a CAR-T or neoantigen-specific T cell therapy. In some embodiments, the method comprises (a) administering a labeled CD8 binding agent to the subject prior to administering the cell therapy and detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue. + (a) administering the cell therapy, and (b) administering the labeled CD8 binding agent to the subject at a time point after the administration of the cell therapy and detecting the binding of the labeled CD8 binding agent to CD8 in the tumor tissue. + T cells, and (d) measurement of CD8 + In some embodiments, the methods are used to explain the mechanism of treatment failure, for example, by tumor CD8 + Loss of cells, by exhaustion and / or by loss of therapeutic potential.
[0247] In some embodiments, the CD8 binding agent is detectably labeled (e.g., 89 Zr, 124 I. 18 F. 68 Ga, etc.), and the labeled CD8 binding agent is detected by PET or PET / CT to bind to CD8 in tumor tissue. + In some embodiments, the CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is a compound of formula (I) and [ 18F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0248] In some embodiments, more than one administration of a CD8 binding agent is used for repeated prediction or monitoring in a subject. In some embodiments, the method or monitoring subject is repeated over an extended period of time, such as at least about 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any ranges between these values.
[0249] Methods for use in autoimmune diseases or conditions, transplant rejection, and graft-versus-host disease
[0250] Due to their high sensitivity and low immunogenicity, the CD8 binding agents described herein are suitable for monitoring disease progression, predicting responsiveness to immunotherapy and / or monitoring treatment progress in subjects with autoimmune diseases or conditions, transplant rejection or graft-versus-host disease. In some embodiments, the immunotherapy is an immunosuppressive agent.
[0251] Provided herein are methods for monitoring treatment progress and disease progression in a subject with an autoimmune disease or condition (e.g., autoimmune arthritis, colitis, celiac disease), transplant rejection, or graft-versus-host disease. Such diseases all involve CD8 + T cells. See Petrelli & Femke, CD8 + T cells in human autoimmune arthritis: the usual suspects; Nature Reviews Thumatology 12:421-428 (2016) The method comprises administering a labeled CD8 binding agent to a subject with or without an intervening treatment, and detecting the binding of the labeled CD8 binding agent to CD8 in a tissue at a first time point and a second time point. + In some embodiments, the CD8 T cells from the first time point and the second time point are +An increase in T cells is an indication that an autoimmune disease or condition, transplant rejection, or graft-versus-host disease has progressed. In some embodiments, the interventional therapy to treat the autoimmune disease or condition, transplant rejection, or graft-versus-host disease is administered before the labeled CD8 binding agent, the first time point is after the administration of the interventional therapy to treat the autoimmune disease or condition, transplant rejection, or graft-versus-host disease, and after the administration of the labeled CD8 binding agent, and the second time point is after the first time point. In some embodiments, a lower level of CD8 in the tissue at the second time point compared to the first time point + T cells indicate positive treatment progress (e.g., beneficial or desired clinical outcome). In some embodiments, higher levels of CD8 T cells in the diseased tissue at the second time point compared to the first time point + T cells indicate a lack of treatment progress (e.g., a lack of beneficial or desired clinical outcome). In some embodiments, CD8 T cells are detected in the tissue at a third, fourth, or fifth later time point. + In some embodiments, the level of CD8 T cells in the tissue is lower at one or more later time points compared to the first time point. + T cells indicate a lack of treatment progress (e.g., a lack of beneficial or desired clinical outcome). In some embodiments, higher levels of CD8 T cells in diseased tissue at one or more later time points compared to the first time point. + T cells indicate a lack of treatment progress (e.g., a lack of beneficial or desired clinical outcome). In some embodiments, the methods are used to explain the mechanism of treatment failure. In some embodiments, the time points are at least about 1 day, 3 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 12 months, 1.5 years, 2 years, 2.5 years, 3 years, or more than three years apart.
[0252] Also provided herein are methods for predicting the responsiveness of a subject with an autoimmune disease or condition, transplant rejection, or graft-versus-host disease to an immunotherapeutic agent (e.g., an immunosuppressant). In some embodiments, the method comprises administering a labeled CD8 binding agent described herein and detecting the binding of the labeled CD8 binding agent to CD8 in a diseased tissue in the subject. + T cells, wherein the detection of said binding indicates that the subject is likely to respond to the immunosuppressant. In some embodiments, the method comprises administering a labeled CD8 binding agent as described herein and detecting the binding of the labeled CD8 binding agent to CD8 in diseased tissue in the subject. + T cell binding, wherein the detection of said binding indicates that the subject is in need of treatment with an immunosuppressant. In some embodiments, the method further comprises administering a therapeutically effective amount of an immunotherapeutic agent to the subject in which binding is detected.
[0253] Further provided are methods of monitoring the progress of treatment in a subject with an autoimmune disease or condition, transplant rejection, or graft-versus-host disease who has been or is receiving an immunotherapeutic agent (e.g., an immunosuppressant). In some embodiments, the method comprises (a) administering a labeled CD8 binding agent to the subject prior to administering the immunotherapeutic agent and detecting binding of the labeled CD8 binding agent to CD8 in diseased tissue. + (a) administering an immunotherapeutic agent, and (b) administering a labeled CD8 binding agent to a subject at a time point after the administration of the immunotherapeutic agent and detecting the binding of the labeled CD8 binding agent to CD8 in the diseased tissue. + T cells, and (d) measuring CD8 + Differences in T cell markers. In some embodiments, lower levels of CD8 T cells in diseased tissue at a time point after administration of the immunotherapeutic agent compared to a time point before administration of the immunotherapeutic agent. + T cells indicate positive treatment progress (e.g., beneficial or desired clinical outcome). In some embodiments, higher levels of CD8 T cells in diseased tissue at a time point after administration of the immunotherapeutic agent compared to a time point before administration of the immunotherapeutic agent. + T cells indicate a lack of treatment progress (e.g., a lack of beneficial or desired clinical outcome). In some embodiments, CD8 T cells are detected in the tissue at one, two, three, four or more later time points. + In some embodiments, the methods are used to explain the mechanism of treatment failure. In some embodiments, the time points are at least about 1 day, 3 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 12 months, 1.5 years, 2 years, 2.5 years, 3 years, or more than three years apart.
[0254] In some embodiments, the CD8 binding agent is detectably labeled (e.g., 89 Zr, 124 I. 18 F. 68 Ga, etc.), and the labeled CD8 binding agent is detected by PET or PET / CT to bind to CD8 in tumor tissue. + In some embodiments, the CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is a compound of formula (I) and [ 18F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0255] In some embodiments, the methods are used for transplant rejection, such as kidney, liver, heart or heart / lung transplant rejection. In some embodiments, the methods are used for autoimmune diseases or conditions, such as hepatitis, lupus (e.g., SLE), vasculitis, and neuritis with demyelination, including multiple sclerosis.
[0256] In some embodiments, the immunotherapeutic agent is an immunosuppressant. Suitable immunosuppressants include, but are not limited to, prednisone, cyclophosphamide, cyclosporine, mycophenolate mofetil, ibrutinib, ruxolitinib, and biologics such as TNF-α antibodies, e.g., adalimumab, etanercept, golimumab, and infliximab.
[0257] In some embodiments, more than one administration of a CD8 binding agent is used for repeated prediction or monitoring in a subject. In some embodiments, the method or monitoring subject is repeated over an extended period of time, such as at least about 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years or longer, including any value or range between these values.
[0258] In some embodiments, CD8 binding agents can enable continuous evaluation of lymphoid tissues and organs associated with cancer, autoimmune diseases or conditions, transplant rejection, or graft-versus-host disease. In some embodiments, one or more levels or one or more signals detected in a subject from a CD8 binding agent can be correlated with other imaging techniques (e.g., MRI). In some embodiments, one or more levels or one or more signals detected in a subject from a CD8 binding agent can be correlated with blood and / or tissue biomarkers (e.g., tissue biopsy biomarkers).
[0259] In some embodiments, the CD8 binding agent enables multiplexed imaging, for example, using another imaging scan, such as a PET, SPECT, or scintigraphy scan.
[0260] In some embodiments, imaging data obtained using a CD8 binding agent is correlated with data from other radiological modalities, such as MRI, CT, ultrasound, or X-ray.
[0261] Pharmaceutical composition
[0262] Compositions are also provided, including pharmaceutical preparations, comprising CD8 binding agents, such as anti-CD8 antibodies (e.g., anti-CD8 VHH), or polynucleotides comprising sequences encoding CD8 binding agents, such as anti-CD8 antibodies (e.g., anti-CD8 VHH). In some embodiments, the compositions comprise one or more CD8 binding agents that bind to CD8, or one or more polynucleotides comprising sequences encoding one or more CD8 binding agents that bind to CD8. These compositions may further comprise a suitable carrier, such as a pharmaceutically acceptable excipient, including a buffer, which is well known in the art.
[0263] In some embodiments, a pharmaceutical composition is provided, comprising any one of the CD8 binding agents described herein (e.g., a labeled CD8 binding agent) and a pharmaceutically acceptable carrier. In some embodiments, a pharmaceutical preparation is provided, comprising any one of the labeled CD8 binding agents described herein and one or more antioxidant compounds, such as methionine and / or N-acetyltryptophan. In some embodiments, the pharmaceutical preparation comprises histidine, methionine, N-acetyltryptophan and / or sucrose. In some embodiments, the pharmaceutical preparation comprises histidine, methionine, N-acetyltryptophan and sucrose.
[0264] By combining such antibodies having the desired purity with one or more optional pharmaceutically acceptable carriers ( Remington's Pharmaceutical Sciences16th edition, Osol, A. ed. (1980)) in the form of a lyophilized formulation or an aqueous solution to prepare a pharmaceutical formulation of a CD8 binding agent as described herein. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid, N-acetyltryptophan, and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 1 0 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions, such as sodium; metal complexes (such as Zn-protein complexes); and / or nonionic surfactants, such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), such as human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (HYLENEX ® , Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, the sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.
[0265] Exemplary lyophilized antibody formulations are described in US Pat. No. 6,267,958. Aqueous antibody formulations include those described in US Pat. No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.
[0266] The formulations herein may also contain more than one active ingredient (e.g., immunotherapeutic agent) as desired for the particular indication being treated (e.g., cancer, autoimmune disease or condition, transplant rejection or graft-versus-host disease), preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide a statin. Such active ingredients are suitably present in combination in amounts effective for the intended purpose.
[0267] The active ingredient can be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions, respectively. This technology is disclosed in Remington's Pharmaceutical Sciences 16th ed., Osol, A. ed. (1980).
[0268] Sustained release preparations can be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, eg films, or microcapsules.
[0269] Formulations for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.
[0270] Products and kits
[0271] In some embodiments, articles of manufacture or kits are provided that include materials for predicting responsiveness of a subject having a disease (e.g., cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease) to an immunotherapeutic agent, for monitoring disease progression in a subject having a disease (e.g., cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease), and / or monitoring the progress of treatment in a subject having a disease (e.g., cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease).
[0272] In some embodiments, an article of manufacture or kit comprises a container containing one or more CD8 binding agents or compositions described herein. In some embodiments, an article of manufacture or kit comprises a container containing one or more nucleic acids or compositions encoding one (or more) CD8 binding agents described herein. In some embodiments, a kit comprises cells of a cell line that produces a CD8 binding agent (e.g., an anti-CD8 antibody) as described herein.
[0273] In some embodiments, the kit or article of manufacture includes an anti-CD8 VHH. In some embodiments, the kit or article of manufacture includes a labeled CD8 binding agent, e.g., an immunoconjugate comprising a detectable label. In some embodiments, the kit includes both an anti-CD8 antibody (e.g., an anti-CD8 VHH) and a labeled CD8 binding agent. In some embodiments, the kit or article of manufacture further includes reagents for preparing the labeled CD8 binding agent, e.g., a chelating agent of formula (I) and [ 18 F]-aluminum fluoride complex.
[0274] In some embodiments, the labeled CD8 binding agent is 18 F-labeled conjugated anti-CD8 VHH. In some embodiments, the CD8 binding agent is a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated anti-CD8 VHH. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-CD8 VHH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-CD8 VHH comprises the amino acid sequence of SEQ ID NO: 4.
[0275] In some embodiments, the kit includes one or more positive controls, such as CD8 (or a fragment thereof) or CD8 + In some embodiments, the kit includes a negative control, such as a surface or solution that is substantially free of CD8.
[0276] In some embodiments, the article or kit includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed of a variety of materials, such as glass or plastic. The container holds a composition, which is combined with another composition that effectively treats, prevents and / or diagnoses cancer, and can have a sterile access port (for example, the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic injection needle). At least one reagent in the composition is a CD8 binder described herein. The label or package insert indicates that the composition is used to predict the responsiveness of a subject with cancer to an immunotherapeutic agent, to monitor disease progression in a subject with cancer, and / or to monitor treatment progress in a subject with cancer.
[0277] In addition, the article of manufacture or kit may include (a) a first container containing a composition, wherein the composition comprises a CD8 binding agent described herein; and (b) a second container containing a composition, wherein the composition comprises a further cytotoxic agent or other therapeutic agent. In some embodiments, the therapeutic agent is an immunotherapeutic agent as described herein.
[0278] The articles or kits provided herein may further include a package insert indicating that one or more compositions can be used to predict the responsiveness of a subject with a disease (e.g., cancer, autoimmune disease or condition, transplant rejection, or graft-versus-host disease) to an immunotherapeutic agent, to monitor disease progression in a subject with a disease (e.g., cancer, autoimmune disease or condition, transplant rejection, or graft-versus-host disease), and / or to monitor treatment progress in a subject with a disease (e.g., cancer, autoimmune disease or condition, transplant rejection, or graft-versus-host disease). In addition, the article may further include a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials that are desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0279] Exemplary embodiments
[0280] This application provides the following implementation schemes:
[0281] 1. A CD8 binding agent comprising a variable domain of a heavy chain of a heavy chain antibody (VHH domain), wherein the CD8 binding agent has a K of about 1 nM or less. D Binds specifically to human CD8.
[0282] 2. The CD8 binding agent of embodiment 1, wherein the CD8 binding agent has a k of about 0.002 / s or less. off Binds human CD8.
[0283] 3. The CD8 binding agent of embodiment 1 or 2, wherein the K D and / or k off The surface plasmon resonance assay is performed using a one-armed human CD8α / human CD8β-Fc fusion protein (eg, a single-chain polypeptide comprising human CD8α and human CD8β fused to one polypeptide chain of Fc) as a reagent.
[0284] 4. The CD8 binding agent of any one of embodiments 1-3, wherein the CD8 binding agent has a K of about 1 nM or less. D Binds to cynomolgus monkey CD8.
[0285] 5. The CD8 binding agent of any one of embodiments 1-4, wherein the CD8 binding agent has a k of about 0.004 / s or less. off Binds to cynomolgus monkey CD8.
[0286] 6. The CD8 binding agent of embodiment 4 or 5, wherein the K D and / or k offThe surface plasmon resonance assay is performed using a one-armed cynomolgus CD8α / cynomolgus CD8β-Fc fusion protein (eg, a single-chain polypeptide comprising cynomolgus CD8α and cynomolgus CD8β fused to one polypeptide chain of Fc) as a reagent.
[0287] 7. The CD8 binding agent of any one of embodiments 1-6, wherein the CD8 binding agent does not stimulate or inhibit CD8 + Activation of T cells.
[0288] 8. The CD8 binding agent of any one of embodiments 1-7, wherein the CD8 binding agent does not induce CD8 + T cell proliferation.
[0289] 9. The CD8 binding agent of any one of embodiments 1-8, wherein the CD8 binding agent does not bind to CD4 + T cells.
[0290] 10. The CD8 binding agent of any one of embodiments 1-9, wherein the VHH domain is an alpaca VHH.
[0291] 11. The CD8 binding agent of any one of embodiments 1-10, wherein the VHH is humanized.
[0292] 12. The CD8 binding agent of any one of embodiments 1-11, wherein the VHH domain specifically binds to a human CD8α epitope comprising Arg25, Lys42, Gln44, Val45, Leu46, Leu47, Ser48, Pro50, Thr51, Ser52, Gln75, Arg93, Leu94, Gly95, Asp96 and Thr97, wherein the amino acid numbering is according to SEQ ID NO: 13.
[0293] 13. The CD8 binder of embodiment 12, wherein the VHH domain comprises a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 6 or 7; a CDR2 comprising the amino acid sequence of SEQ ID NO: 8 or 9; and a CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 10-12.
[0294] 14. The CD8 binding agent of embodiment 13, wherein the VHH domain comprises:
[0295] (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 10;
[0296] (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11;
[0297] (3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 11; or
[0298] (4) CDR1 comprising the amino acid sequence of SEQ ID NO: 6, CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and CDR3 comprising the amino acid sequence of SEQ ID NO: 12.
[0299] 15. The CD8 binder of embodiment 13, wherein the VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 12.
[0300] 16. The CD8 binding agent of any one of embodiments 1-15, wherein the VHH domain comprises L49A, wherein the numbering is according to Kabat numbering.
[0301] 17. The CD8 binding agent of any one of embodiments 1-16, wherein the VHH domain comprises one or more amino acid modifications selected from a V89T substitution, a T110Q substitution, a S112Q substitution and an A114 addition, wherein the numbering is according to Kabat numbering.
[0302] 18. The CD8 binding agent of any one of embodiments 1-17, wherein the VHH domain comprises the amino acid sequence of any one of SEQ ID NOs: 1-4.
[0303] 19. The CD8 binding agent of any one of embodiments 1-18, wherein the agent does not comprise an Fc region.
[0304] 20. An isolated nucleic acid encoding the CD8 binding agent of any one of embodiments 1-19.
[0305] 21. An expression vector comprising the nucleic acid of embodiment 20.
[0306] 22. A host cell comprising the nucleic acid of embodiment 20 or the expression vector of embodiment 21.
[0307] 23. The host cell of embodiment 22, wherein the host cell is a eukaryotic cell.
[0308] 24. The host cell of embodiment 23, wherein the host cell is a mammalian cell.
[0309] 25. The host cell of embodiment 24, wherein the host cell is an Expi293 cell.
[0310] 26. The host cell of embodiment 22, wherein the host cell is a prokaryotic cell.
[0311] 27. A method for preparing a CD8 binding agent, the method comprising:
[0312] a) culturing the host cell of any one of embodiments 22-26 under conditions wherein the agent is produced; and
[0313] b) Recovering the CD8 binder produced by the host cells.
[0314] 28. The CD8 binding agent of any one of embodiments 1-19, wherein the VHH domain is conjugated to a label.
[0315] 29. The CD8 binding agent of embodiment 28, wherein the label is a fluorescent dye, a radionuclide or an enzyme.
[0316] 30. The CD8 binding agent of embodiment 29, wherein the label is a radionuclide.
[0317] 31. The CD8 binding agent of embodiment 30, wherein the radionuclide is 18 F. 89 Zr, 99m Tc, 67 Ga, 68 Ga, 64 Cu, 52 Mn, 111 In or 124 I.
[0318] 32. The CD8 binding agent of any one of embodiments 28-31, wherein the VHH domain is conjugated to a label via a chelating moiety.
[0319] 33. The CD8 binding agent of embodiment 32, wherein the chelating moiety is covalently linked to the VHH domain via a lysine residue.
[0320] 34. The CD8 binding agent of embodiment 32 or 33, wherein the label forms a complex with a metal, wherein the complex is chelated by a chelating moiety.
[0321] 35. The CD8 binding agent of embodiment 34, wherein the label is 18 F and the metal is aluminum.
[0322] 36. The CD8 binding agent of embodiment 35, wherein the chelating moiety is a compound of formula (I):
[0323] .
[0324] 37. Detection of CD8 in the subject + A method for a cell, the method comprising:
[0325] a) administering to said subject a labeled CD8 binding agent according to any one of embodiments 28-36; and
[0326] b) detecting the binding of the labeled CD8 binding agent to CD8 in the subject + cells, wherein detection of said binding indicates the presence of CD8 + cell.
[0327] 38. The method of embodiment 37, wherein the labeled CD8 binding agent is detected to be CD8 in the subject. + The binding of cells includes CD8 + Cells were imaged.
[0328] 39. The method of embodiment 38, wherein the CD8 + Imaging the cells may include performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan of the subject.
[0329] 40. The method according to any one of embodiments 37-39, wherein the CD8 + The cells are CD8 + T cells.
[0330] 41. The method according to any one of embodiments 37-40, wherein the CD8 + The cells are CD8 + Tumor cells.
[0331] 42. The method according to any one of embodiments 37-41, wherein the detecting is performed within about 1 day or less after administration.
[0332] 43. The method according to any one of embodiments 37-42, wherein the method is repeated one or more times.
[0333] 44. The method of embodiment 43, wherein the method is repeated about 1 day after the pre-administration of the CD8 binding agent.
[0334] 45. The method of embodiment 43 or 44, wherein the method is repeated 1 to 4 times per year.
[0335] 46. The method according to any one of embodiments 43-45, wherein the method is repeated for more than 1 year.
[0336] 47. The method of any one of embodiments 37-46, wherein the method has a sensitivity of about 1 nM to about 30 nM.
[0337] 48. The method of any one of embodiments 37-47, wherein the subject is a human or a non-human primate.
[0338] 49. The method of embodiment 48, wherein the non-human primate is a cynomolgus monkey or a rhesus monkey.
[0339] 50. The method of embodiment 48, wherein the subject is a human.
[0340] 51. The method of any one of embodiments 37-50, wherein the subject suffers from cancer.
[0341] 52. The method according to any one of embodiments 37-50, wherein the subject suffers from an autoimmune disease, transplant rejection or graft-versus-host disease.
[0342] 53. A method of predicting responsiveness of a subject having cancer to an immunotherapeutic agent, a cell therapy, or a cancer vaccine, the method comprising:
[0343] a) administering to said subject a labeled CD8 binding agent according to any one of embodiments 28-36; and
[0344] b) detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue in the subject + T cells, wherein detection of said binding indicates that said subject is likely to respond to said immunotherapeutic agent, cell therapy or cancer vaccine.
[0345] 54. The method of embodiment 53, further comprising the steps of:
[0346] (c) administering a therapeutically effective amount of an immunotherapeutic agent, cell therapy, or cancer vaccine to a subject in which binding has been detected.
[0347] 55. A method of monitoring disease progression in a subject suffering from cancer, the method comprising:
[0348] a) administering to the subject a labeled CD8 binding agent according to any one of embodiments 28-36, and
[0349] b) detecting the binding of the labeled CD8 binding agent to CD8 in tumor tissue in the subject at a first time point and a second time point. + Binding of T cells.
[0350] 56. The method of embodiment 55, further comprising the steps of:
[0351] (c) administering to the subject a therapeutically effective amount of an immunotherapeutic agent, a cell therapy, or a cancer vaccine, wherein at the second time point, the number of CD8 + The level of T cells was higher than that of CD8 T cells in tumor tissue at the first time point. + T cell levels.
[0352] 57. A method of monitoring the progress of treatment in a subject having cancer who has been or is receiving an immunotherapeutic agent, a cell therapy, or a cancer vaccine, the method comprising:
[0353] i) administering to the subject the labeled CD8 binding agent of any one of embodiments 28-36 together with the immunotherapeutic agent, cell therapy or cancer vaccine, and
[0354] ii) detecting the binding of the labeled CD8 binding agent to CD8 in the tumor tissue at the first time point and the second time point + Binding of T cells.
[0355] 58. The method of embodiment 57, wherein the labeled CD8 binding agent is administered before the immunotherapeutic agent, cell therapy, or cancer vaccine, wherein the first time point is after administration of the labeled CD8 binding agent and before administration of the immunotherapeutic agent, cell therapy, or cancer vaccine, and wherein the second time point is after administration of the immunotherapeutic agent, cell therapy, or cancer vaccine.
[0356] 59. The method of embodiment 57, wherein the immunotherapeutic agent, cell therapy or cancer vaccine is administered before the labeled CD8 binding agent, wherein the first time point is after administration of the immunotherapeutic agent, cell therapy or cancer vaccine and after administration of the labeled CD8 binding agent, and wherein the second time point is after the first time point.
[0357] 60. The method of any one of embodiments 53-54 and 56-59, wherein an immunotherapeutic agent is administered to the subject.
[0358] 61. The method of embodiment 60, wherein the immunotherapeutic agent is an anti-PDL1 antibody, an anti-PD1 antibody, an anti-TIGIT antibody, a TIGIT antagonist, an anti-CSF-1R antibody, an anti-CSF-1R antagonist, an anti-CEA antibody, an anti-CEA antagonist, an anti-CTLA4 antibody, a CTLA4 antagonist, an anti-OX40 antibody or an OX40 agonist.
[0359] 62. The method of embodiment 61, wherein the immunotherapeutic agent is an anti-PD-L1 antibody.
[0360] 63. The method of embodiment 62, wherein the anti-PD-L1 antibody is atezolizumab.
[0361] 64. The method of embodiment 62 or 63, wherein the anti-PD-L1 antibody is administered in combination with one or more therapeutic agents.
[0362] 65. The method of embodiment 64, wherein the one or more therapeutic agents is TARCEVA ® (erlotinib), ZELBORAF ® (Vemurafenib), GAZYVA ® (Atozumab), AVASTIN ® (bevacizumab), COTELLIC ® (cobimetinib), ZELBORAF ® (Vemurafenib) and COTELLIC ® (cobimetinib), ALECENSA ® (Alectinib), KADCYLA ® (trastuzumab emtansine conjugate), HERCEPTIN ® (trastuzumab), PERJETA ® (pertuzumab), polotuzumab, INF-α, anti-CD40 agents, anti-OX40 antibodies, OX40 agonists, anti-CSF-1R antibodies, anti-CEA antibodies, IDO inhibitors, or anti-TIGIT antibodies.
[0363] 66. The method of embodiment 60, wherein the immunotherapeutic agent is a cytokine.
[0364] 67. The method of embodiment 66, wherein the cytokine is IL2, artificially modified IL2, IL15 or artificially modified IL15.
[0365] 68. The method of embodiment 60, wherein the immunotherapeutic agent is a bispecific antigen binding molecule that specifically binds CD3.
[0366] 69. The method of embodiment 60, wherein the immunotherapeutic agent is a bispecific antigen binding molecule that specifically binds CD16.
[0367] 70. The method of embodiment 68 or 69, wherein the bispecific antigen binding molecule is an antibody or an antigen binding fragment thereof.
[0368] 71. The method of embodiment 69 or 70, wherein the bispecific antigen binding molecule specifically binds CD16A.
[0369] 72. The method of embodiment 60, wherein the immunotherapeutic agent is a dendritic cell modulator.
[0370] 73. The method of embodiment 72, wherein the immunotherapeutic agent is a dendritic cell activator or a dendritic cell growth factor.
[0371] 74. The method of any one of embodiments 53-54 and 56-59, wherein a cancer vaccine is administered to the subject.
[0372] 75. The method of embodiment 74, wherein the cancer vaccine is a personalized cancer vaccine (PCV).
[0373] 76. The method of any one of embodiments 53-54 and 56-59, wherein cell therapy is administered to the subject.
[0374] 77. The method of embodiment 76, wherein the cell therapy is CAR-T or neoantigen-specific T cells.
[0375] 78. A method of predicting responsiveness to an immunotherapeutic agent in a subject suffering from an autoimmune disease, transplant rejection or graft-versus-host disease, the method comprising:
[0376] a) administering to said subject a labeled CD8 binding agent according to any one of embodiments 28-36; and
[0377] b) detecting the binding of the labeled CD8 binding agent to CD8 in the diseased tissue of the subject + T cells, wherein detection of said binding indicates that said subject is likely to respond to the immunotherapeutic agent.
[0378] 79. The method of embodiment 78, further comprising the steps of:
[0379] (c) administering to the subject in which binding has been detected a therapeutically effective amount of an immunotherapeutic agent.
[0380] 80. A method of monitoring disease progression in a subject suffering from an autoimmune disease, transplant rejection or graft-versus-host disease, the method comprising:
[0381] a) administering to the subject a labeled CD8 binding agent according to any one of embodiments 28-36, and
[0382] b) detecting the binding of the labeled CD8 binding agent to CD8 in the diseased tissue of the subject at a first time point and a second time point + The combination of T cells, wherein the CD8 + An increase in T cells indicates that the autoimmune disease, transplant rejection or graft-versus-host disease has progressed.
[0383] 81. The method of embodiment 80, further comprising the steps of:
[0384] (c) administering to the subject a therapeutically effective amount of an immunotherapeutic agent, wherein at the second time point, the CD8 + T cell levels were lower than those in the diseased tissue at the first time point, CD8 + T cell level.
[0385] 82. A method of monitoring the progress of treatment in a subject having an autoimmune disease, transplant rejection or graft-versus-host disease, said subject having been or being treated with an immunotherapeutic agent, said method comprising:
[0386] i) administering to said subject a labeled CD8 binding agent according to any one of embodiments 28 to 36 together with said immunotherapeutic agent, and
[0387] ii) detecting the binding of the labeled CD8 binding agent to CD8 in the diseased tissue at the first time point and the second time point + Binding of T cells.
[0388] 83. The method of embodiment 82, wherein the labeled CD8 binding agent is administered before the immunotherapeutic agent, wherein the first time point is after administration of the labeled CD8 binding agent and before administration of the immunotherapeutic agent, and wherein the second time point is after administration of the immunotherapeutic agent.
[0389] 84. The method of embodiment 82, wherein the immunotherapeutic agent is administered before the labeled CD8 binding agent, wherein the first time point is after administration of the immunotherapeutic agent and after administration of the labeled CD8 binding agent, and wherein the second time point is after the first time point.
[0390] 85. The method of any one of embodiments 53-84, wherein the labeled CD8 binding agent is detected to be CD8 in the subject +T cells include CD8 + T cells were imaged.
[0391] 86. The method of embodiment 85, wherein the CD8 + Imaging T cells may include performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan on the subject.
[0392] 87. The method of any one of embodiments 53-86, further comprising performing another imaging scan (eg, PET, SPECT, or scintigraphy scan) within about 48 hours after imaging using said labeled CD8 binding agent.
[0393] 88. The method of any one of embodiments 55-77 and 80-87, wherein the subject is monitored for at least 1 year.
[0394] 89. A method of identifying intestinal microbial strains associated with responsiveness to treatment with an immunotherapeutic agent, comprising:
[0395] a) obtaining a gut microbiome sample from a population of subjects having cancer, the population comprising subjects that respond to treatment with an immunotherapeutic agent and subjects that do not respond to treatment with an immunotherapeutic agent;
[0396] b) analyzing gut microbiome samples from subjects who responded to treatment and gut microbiome samples from subjects who did not respond to treatment; and
[0397] c) identifying intestinal microbial strains associated with a subject that responds to treatment; wherein the responsiveness is determined by detecting the labeled CD8 binding agent of any one of embodiments 28-36 and CD8 in tumor tissue in the subject. + T cells, and wherein detection of said binding indicates that said subject is responsive to the immunotherapeutic agent.
[0398] 90. The method of embodiment 89, further comprising preparing a microbiome-based medicine comprising a gut microbial strain associated with responsiveness to an immunotherapeutic agent.
[0399] 91. The method of embodiment 89 or 90, wherein the immunotherapeutic agent is an anti-PD-1 antibody.
[0400] 92. The method of embodiment 89 or 90, wherein the immunotherapeutic agent is an anti-PD-L1 antibody.
[0401] 93. The method of embodiment 92, wherein the anti-PD-L1 antibody is atezolizumab.
[0402] 94. A kit comprising the labeled CD8 binding agent of any one of embodiments 28-36.
[0403] 95. A method for preparing a labeled CD8 binding agent, comprising conjugating a chelating moiety to the VHH domain of the CD8 binding agent of any one of embodiments 1-19 to provide a conjugate, and mixing the conjugate with a 18 F to provide a labeled CD8 binding agent, wherein the chelating moiety is a compound of formula (I):
[0404] .
[0405] 96. The method of embodiment 95, wherein the conjugate is contacted with the aluminum fluoride complex in the presence of one or more antioxidant compounds.
[0406] 97. The method of embodiment 96, wherein the one or more antioxidant compounds include methionine and / or N-acetyl-tryptophan.
[0407] 98. A pharmaceutical formulation comprising the CD8 binding agent of any one of embodiments 1-19 and 28-36 and one or more antioxidant compounds.
[0408] 99. The pharmaceutical formulation of embodiment 98, wherein the one or more antioxidant compounds are methionine and / or N-acetyltryptophan.
[0409] 100. The pharmaceutical formulation of embodiment 98 or 99, further comprising histidine and sucrose.
[0410] Example
[0411] Example 1: Development and characterization of VHHs against human CD8
[0412] Discovery and initial screening of anti-CD8 VHHs
[0413] Alpacas were immunized with either of two antigens, a C-terminal hFc-tagged CD8α receptor (CD8α-Fc) or a C-terminal histidine-tagged single-chain protein in which CD8α was fused to CD8β via a linker (CD8αβ-His). Standard immunization protocols were performed as described in Ghahroudi et al. FEBS 1997 (see also U.S. Patent No. 6,015,695). Using standard RT-PCR methods, the VHH heavy chain repertoire was amplified and cloned into a phagemid vector to construct an immune phage library. Several rounds of in vitro selection of the phage library were then performed using CD8αβ-His or CD8α-Fc with varying concentrations, washing times, and elution conditions. After three and four rounds of selection, individual phage clones were characterized by ELISA and subjected to Sanger sequencing.
[0414] In addition, the binding affinity of the selected VHH antibodies to both human (huCD8a-Fc) and cynomolgus monkey (cynoCD8a-Fc) CD8 was determined by SPR. In particular, 2C8.1-H (also referred to herein as "wt2C8") exhibited acceptable affinity and binding to huCD8+ HPBALL cells ( Figure 3 ).
[0415] VHH expression and purification
[0416] Unique sequences identified from phage panning were expressed in a mammalian expression vector containing a C-terminal His tag. The expressed VHHs were subjected to two-step purification: Ni Sepharose excel labeled histidine protein purification resin (GE Healthcare) followed by size exclusion chromatography (SEC). Untagged VHHs were also expressed in mammalian cells. Untagged VHHs were subjected to ion exchange purification (SP column) or recombinant protein A resin (GORE) followed by SEC.
[0417] SPR characterization
[0418] The binding affinity of each VHH variant to both human (one-armed single-chain huCD8α / huCD8β-Fc) and cynomolgus monkey (one-armed single-chain cynoCD8α / cynoCD8β-Fc) was determined by surface plasmon resonance (SPR). SPR experiments were performed on a BiacoreT200 (GE Healthcare) at 37°C using HBS-P+ (GE Healthcare) running buffer. 1.5 μg / mL of CD8αβ-Fc was captured using an anti-HuIgG1 Fc capture kit (GE Healthcare), and monomeric VHHs were added as analytes in solution at a flow rate of 100 μL / min. VHHs were titrated using a dilution series from 100-0 nM. Sensorgrams were fitted to a 1:1 Langmuir model to identify kinetic parameters, including K D , k on and k off .
[0419] CD8 + Identification of cell-specific VHH variants
[0420] Recombinant VHHs fused to a C-terminal huIgG1 Fc were expressed, purified, and screened by FACS against huCD8+ HPBALL cells, a human T-cell leukemia cell line expressing CD8 (DSMZ, Germany). Human embryonic kidney cells (HEK) obtained from ATCC were included as a non-CD8 expressing control cell line. Approximately 300,000 cells were plated in round-bottom 96-well plates in the presence of 100 μL RPMI medium (Thermo Fisher Scientific) supplemented with 10% v / v fetal bovine serum and 1% v / v penicillin-streptomycin. VHH variants fused to human-IgG Fc were incubated with cells at a concentration of 10 μg / mL for 60 min at 37°C. Unbound VHHs were then washed away and ALEXA FLUOR ® 647 goat anti-human IgG Fc antibody (Jackson Immuno Research, Inc.) was added to the cells at a concentration of 7.5 μg / mL for 60 minutes at 37°C. The cells were then washed twice with phosphate-buffered saline (pH 7.4) supplemented with 0.5% bovine serum albumin and analyzed by FACSCalibur flow cytometer (BD Biosciences). Samples were analyzed in duplicate. OKT8-Fc, derived from a four-chain antibody that binds to human CD8a, served as a positive control.
[0421] The results are shown in Figure 3, which showed that 2C8 VHH-Fc had similar affinity and binding to HPBALL cells as OKT8-Fc.
[0422] Binds to whole blood cells and PBMCs
[0423] 2C8 VHH was selected for further FACS analysis of human whole blood and corresponding PBMC samples. VHH was expressed as His-tagged monomers and directly analyzed by ALEXA FLUOR ® 647 mark.
[0424] Briefly, whole blood samples from 4 healthy donors (Health center, Genentech) were collected at room temperature and processed less than 30 minutes after blood draw. For each donor, 1 mL of sample was reserved for direct staining, and 4 mL of sample was used for peripheral blood mononuclear cells (PBMCs) isolation (Ficoll-Paque separation) before staining. To avoid nonspecific binding, whole blood or PBMCs were mixed with 1000 μL or 10 μL of PBS, respectively, before staining. 7 20 μL FcR blocking reagent (Miltenyi Biotech) was incubated with 100 μL whole blood or 5×10 4 PBMCs were distributed into 96-well plates for flow cytometry staining. ® Preparation of fluorescently labeled antibodies by conjugation of 647 (AF647) dye.
[0425] OKT8-AF647 or VHH-AF647 variants (20 ng / mL), anti-CD14 VioBlue (Miltenyi Biotech; 1 / 25), anti-CD16 PerCP Cy5.5 (Becton-Dickinson; 1 / 200), anti-CD4 VioBright-FITC (Miltenyi Biotech; 1 / 50), anti-CD3 APC-Vio770 (Miltenyi Biotech; 1 / 50) were added as a premixed antibody cocktail for 10 minutes at room temperature. The samples were then resuspended with 2 mL of erythrocyte lysis solution (Becton Dickinson), mixed thoroughly and incubated at room temperature for 10 minutes, followed by centrifugation at 1500 rpm for 5 minutes. After removing the supernatant, the pellet was washed with PBS 1X, BSA 0.5%, and then sampled on a MacsQuant 10 analyzer (Miltenyi Biotech).
[0426] The same protocol was used for PBMC staining except that the erythrocyte lysis step was not performed.
[0427] Figure 4 Results using whole blood samples are shown. OKT8 and 2C8 VHH showed similar staining patterns, including CD8 + Strong staining of T cells and CD3 - Experiments with PBMC samples produced similar results. 2C8 VHH only bound to CD3 in both whole blood (which contains both multinucleated and mononucleated cells) and PBMC (which contains only mononucleated cells). + CD8 + The T cell population bound strongly, confirming specificity for human CD8.
[0428] Structural characterization
[0429] To define the epitope of 2C8 on CD8α, the crystal structure of 2C8 bound to homodimeric CD8αα was determined ( Figure 5 ). 2C8 binds to the apex of CD8α and contacts Arg25, Lys42, Gln44, Val45, Leu46, Leu47, Ser48, Pro50, Thr51, Ser52, Gln75, Arg93, Leu94, Gly95, Asp96, and Thr97. Each of these CD8α amino acid residues is within approximately 4.5 Å of one or more amino acid residues of 2C8 in the crystal structure. The epitope does not overlap with the binding epitope of mouse CD8αβ in complex with MHCI (Wang et al., J Immunol 2009).
[0430] Affinity maturation via NNK walk of VHH CDRs
[0431] In the absence of some half-life extension mechanism such as PEGylation as described by Rashidian et al. JEM 2017, the initial affinity of 2C8 was considered suboptimal for sensitive detection of CD8+ cells. To identify mutations in 2C8 that improved affinity, we performed NNK walking of the CDRs of 2C8 as described by Koenig et al. JBC 2015.
[0432] Briefly, a CDR NNK scanning library was generated in which each mutant contained a single mutation and the entire library included all 20 amino acids at each CDR position in VHH. The library was cloned into a phagemid vector and subjected to several rounds of phage panning against CD8α-hFc with decreasing needle concentrations and increasing wash times. VHH domains were amplified from the initial library and from the library selected in the third round and subjected to next-generation sequencing (NGS). NGS was performed on the amplified DNA amplicons using a MiSeq (Illumina) instrument. The enrichment rate was determined by dividing the frequency of each mutation after 3 rounds of selection by the frequency of each mutation in the initial library.
[0433] When analyzing the NGS results, we observed strong enrichment for A99G and A100fD. Generating 2C8 with A99G and A100fD mutations improved affinity to ~10-fold compared to the parental clone.
[0434] Humanization of 2C8
[0435] We humanized 2C8 by grafting CDRs (30-35 (H1), 50-65 (H2), and 94-102 (H3)) onto IGHV3-23*04. All Vernier positions from alpaca were also grafted to their respective positions. We left several alpaca residues in the framework (F37, R45, G47, and L49) because these are required to maintain binding, stability, and soluble expression of the VHH. After SPR characterization, we determined that only the S71 and V78 Vernier residues were required to maintain high affinity binding. Upon humanization, we noticed very poor binding to the protein A resin despite having preferred residues at all protein A contact sites (as described in Henry et al., PLoS One 2016). We examined potential residues beyond those that directly contact protein A that could indirectly alter the conformation of VHH residues important for protein A binding. We identified L49 as one such residue. Upon mutation to Ala (L49A), we observed a large increase in VHH recovery following purification via the Protein A residues (Table 3).
[0436] Table 3: Yield of purified VHHs after protein A and SEC purification
[0437] clone Yield (mg expressed from 30mL Expi293) Hu2C8 0.256 Hu2C8.L49A 2.493
[0438] Reduced binding to pre-existing ADAs
[0439] Previous clinical data on VHHs have shown pre-existing anti-VHH antibodies in patients [Cordy et al., Clin Exp Immunol 2015; Holland et al., J Clin Immunol 2013; Papadopoulos et al., Cancer Chemother Pharmacol 2015]. We evaluated the binding of VHH variants to pre-existing anti-VHH antibodies and introduced four framework mutations (V89T, T110Q, S112Q, and A114 addition) to mitigate the risks associated with binding to these pre-existing antibodies.
[0440] For VHH anti-drug antibody assay, VHH variants were coated on Maxisorp plates at 2 μg / mL in PBS overnight at 4°C. Plates were washed with PBS + 0.5% BSA + 0.1% Tween 20 (PBSBT) and blocked with 2% BSA for 2 hours at 25°C. Individual serum samples from 96 different healthy donors were diluted 1:50 and incubated with VHH-coated and empty wells for 1-2 hours at 25°C with shaking. After washing, anti-human Fc-specific HRP 2° antibody (1:10,000) was added for 30 minutes at 25°C with shaking. After washing with PBSBT, the plates were developed with TMB substrate for 10 minutes and detected at 650nm.
[0441] like Figure 6 As shown in , framework mutations abolished binding of anti-CD8 VHH to pre-existing anti-VHH antibodies pooled from 96 healthy donors.
[0442] In summary, we developed several humanized and optimized clones (v130, v142, and v144) that strongly bound to human and cynomolgus CD8α. Figure 1 and Table 4 show the amino acid sequences of exemplary VHH clones.
[0443] Table 4. VHH sequences
[0444]
[0445]
[0446] Tables 5 and 6 show the affinity of 2C8v142 and 2C8v144 for αβ, respectively, as determined by SPR. 2C8v144 has a high affinity for human and cynomolgus CD8α, and a relatively slow off rate. Compared to 2C8v144, the 2C8v142 clone contains a W98F mutation in CDR3, which makes 2C8v142 less susceptible to oxidation when exposed to high levels of radiation than 2C8v144.
[0447] Table 5. Affinity of 2C8v142 for human and cynomolgus monkey CD8αβ
[0448]
[0449] Table 6.2 Affinity of C8v144 for human and cynomolgus monkey CD8αβ
[0450]
[0451] Effects on T cell function
[0452] To evaluate the binding of 2C8 VHH to CD8 + To investigate the potential impact on T cell function, we performed in vitro T cell proliferation assays in the presence of 2C8.v130.
[0453] Briefly, freshly isolated PBMCs from three healthy donors were washed in PBS 1X and cultured at 10 × 10 6 The pellet was resuspended at 100 cells / ml. An equal volume of freshly prepared carboxyfluorescein succinimidyl ester (CFSE) 2.5 μM working solution (Molecular Probe) was added before incubation at room temperature for 5 minutes. Labeling was stopped by adding 9 volumes of RPMI, 10% FBS before centrifugation at 1500 rpm for 5 minutes. Two additional washes were performed with RPMI, 10% FBS medium before cell counting and distribution.
[0454] 100,000 CFSE-labeled cells were plated in round-bottom 96-well plates for polyclonal stimulation with 0.2 μg / mL anti-CD3 (Becton Dickinson; pre-coated plates) plus freshly added 1 μg / mL anti-CD28 or 0.4 μg / mL superantigen Staphylococcal enterotoxin B (SEB) (TruCulture tubes; Myriad RBM). For antigen-specific stimulation, 500,000 CFSE-labeled cells were plated in round-bottom 96-well plates and 2 μg / mL CEF peptide pool (Mabtech) was added to each well. 10 ng / mL lipopolysaccharide ("LPS", Sigma) was used as an innate cell activator control, and culture medium alone (RPMI, 10% FBS) was used as a negative control. Finally, for all conditions, PBS 1X, 2C8v130 VHH (1 μg / mL and 10 μg / mL final concentrations) or Lys2 VHH (10 μg / mL), control were added in triplicate to a final volume of 200 μL per well. The control Lys2 VHH binds lysozyme and is described in De Genst et al., JBC 2005.
[0455] In addition, to evaluate the potential influence of circulating human blood molecules on the effect of VHH binding, the FBS in the culture medium was replaced with 10% autologous plasma in the absence of stimulation or in the presence of SEB 0.4 μg / mL. The plates were incubated at 37°C for 5 days before analysis.
[0456] After centrifugation of the plate, the supernatant was removed and the pellet was washed once with PBS 1X. 100 μL of diluted fixable viability dye solution (Live Dead Aqua, ThermoFischer) was added and the cells were incubated at 4°C for 15 minutes and then washed with PBS, 0.5% BSA. A premixed antibody cocktail containing anti-CD4 APC-Vio770 (Miltenyi Biotech; 1 / 50), anti-CD3 Pacific Blue (Becton Dickinson; 1 / 100), and anti-CD8α APC (Becton Dickinson; 1 / 100) was added to the pellet. The cells were incubated on ice for 20 minutes, followed by PBS washing and flow cytometric analysis using MacsQuant 10 (Miltenyi Biotech).
[0457] Figures 7A-7E Shown are the results of a proliferation assay using CFSE-labeled human PBMCs (n=3) in the presence of high (10 μg / mL) or lower (1 μg / mL) saturating concentrations of 2C8.v130, high concentration (10 μg / mL) of a non-CD8-binding VHH (Lys2), or PBS (vehicle). Fig. 7A ), 2C8.v130 and Lys2-VHH did not induce background proliferation in the three donors tested, indicating that the addition of CD8 + VHHs with or without cell binding did not trigger nonspecific T cell activation. Upon anti-CD3 / CD28 polyclonal stimulation ( Figure 7B ), optimal CD8 + T cells proliferated (more than 90% CFSE dilution), and the addition of 2C8.v130 or Lys2 VHH had no effect on T cell activation. The superantigen SEB induced cross-linking between MHC-II and TCR, but the addition of SEB to the samples did not provide optimal proliferation rates (less than 15% CFSE dilution) due to high cell death. Nevertheless, for a single donor, no significant differences were observed between the different conditions ( Figure 7CTo mimic a more physiological MHC-I / TCR / CD8 complex engagement, the CEF peptide library was used to activate TCR-specific CD8 + However, none of the donors tested had detectable reactive CD8 + T cells, since the proliferation rate is similar to that in culture conditions ( Fig.7D ), confirming the absence of VHH-induced background proliferation. In the same way, upon TLR4 stimulation of monocytes (LPS condition), no indirect T cell proliferation was observed when VHHs were added ( Fig. 7E ).
[0458] Figures 8A-8D The results of proliferation assays using 10% FBS or autologous donor plasma as culture medium were compared. Autologous donor plasma samples were obtained prior to PBMC isolation and used in proliferation assays to simulate physiological conditions. In the absence of stimulation, no differences were observed between experiments using 10% FBS culture medium or autologous donor plasma for all donors ( Fig. 8A and 8B ). Therefore, VHHs also do not induce background T cell proliferation in the presence of soluble human plasma factors.
[0459] Example 2: Evaluation of 2C8v144 VHH for molecular imaging
[0460] Labeling of 2C8 VHHs
[0461] For the generation of RESCA (constrained chelator)-modified VHH and 18 F-AlF-RESCA-modified VHH (including 18 F control VHH and 18 The procedure for preparing anti-CD8 VHH (F) was modified from a previously described protocol (Cleeren F. et al., Nature Protocols 13, 2330-2347 (2018)). An exemplary RESCA has the chemical structure of formula (I). Briefly, RESCA-conjugated VHHs were added to a reaction medium consisting of sodium acetate or sodium acetate with methionine and N-acetyl-tryptophan. 18 The reaction mixture was purified using a desalting column equilibrated with a formulation buffer adjusted with histidine, methionine, N-acetyltryptophan and sucrose, which reduces the oxidation rate on the VHH. As a control, the formulation buffer was adjusted with phosphate-buffered saline. The pH and temperature of the histidine formulation buffer were carefully controlled to limit 18Dissociation rate of F-A1F from RESCA. Protein concentration, protein purity and radiochemical purity of the final product were determined by SE-HPLC, and target binding (immunoreactive fraction, when appropriate) was determined by SE-HPLC and SPR.
[0462] Using 2C8v145 VHH 18 F control VHH and using 2C8v144 18 F anti-CD8 VHH was obtained with 40-60% radiochemical yield (non-decay corrected). The final product showed a specific activity range of 3.0-8.0 Ci / μmol, more than 95% radiochemical purity, and 18 F Anti-CD8 VHH, more than 94% immunoreactive fraction.
[0463] Without being bound by any theory or hypothesis, conjugation of anti-CD8 VHHs to radionuclide labels may result in oxidation of one or more VHH residues, such as tryptophan, which results in reduced CD8 binding capacity. The use of antioxidant compounds, such as methionine and / or N-acetyltryptophan, in the conjugation reaction buffer, purification buffer, and / or formulation buffer may reduce oxidation of VHH residues, thereby improving the yield of functionally labeled anti-CD8 VHHs.
[0464] Chimeric CD8 in mice + PET imaging of tumor xenografts
[0465] Assessed by PET imaging of chimeric CD8+ tumor xenografts in mice 18 F—Sensitivity and dynamic range of anti-CD8 VHHs.
[0466] Briefly, HPBALL, a human T-cell leukemia cell line expressing CD8 (DSMZ, Germany), was mixed with Daudi, a human lymphoma cell line lacking CD8 (DSMZ, Germany) at different ratios to generate chimeric tumors with different CD8 concentrations for use 18 F-PET imaging of anti-CD8 VHH. Briefly, female CB17.SCID.bg mice were inoculated with 10 million cells each in a 50:50 mixture of HBSS:matrigel subcutaneously into the dorsal thoracic region. Once tumors reached approximately 400 mm 3 size, the animals were injected via the tail vein 18 F-anti-CD8 VHH, and underwent dynamic 60-min PET scanning on an Inveon PET / computed tomography (CT) scanner (Siemens Preclinical Solutions, Inc.).
[0467] To evaluate CD8 expression after PET imaging, chimeric tumors were excised from mice and dissociated using a gentleMACS Octo Dissociator (Miltenyi Biotec) according to the manufacturer's protocol. The resulting cell suspension was then passed through a 70 μm cell strainer (Corning) to remove aggregates. Tumor cells were then counted and 300,000 cells were plated in a round-bottom 96-well plate with 100 μL of RPMI medium. ALEXA FLUOR ® The cells were stained with 647-labeled OKT8 anti-CD8 antibody (60 min, 4°C) and Sytox orange dead cell stain (15 min, 4°C) (Thermo Fisher Scientific). The cells were washed and then analyzed by FACSCalibur flow cytometer to determine the expression of CD8 + The percentage of cells.
[0468] like Fig. 9 As shown in 18 F-anti-CD8 VHH allows for the expression of proteins as low as 10% CD8 + HPBALL cells clearly showed CD8 + Tumor cells. The results also show PET uptake (%ID / g) and CD8 + Based on previous FACs data, it is estimated that each HPBALL cell has approximately 55,000-85,000 copies of CD8 molecules, while each naive CD8 + T cells have 200,000-300,000 copies of the CD8 molecule. 18 F-anti-CD8 VHH is a sensitive imaging agent that can detect low levels (about 1-30 nM sensitivity) of CD8 expression on tumor cells.
[0469] PET imaging of TALL1 tumor xenografts in mice
[0470] 18 F-anti-CD8 VHH and 89 Zr-one-armed ("OA")-anti-CD8 antibody (see, International Patent Application Publication No. WO2019 / 033043A2) was used to image TALL1 tumor xenografts in mice. TALL1 is a low CD8 expressing leukemia cell line. Based on previous FACS data, it is estimated that each TALL1 cell has approximately 12,000-15,000 copies of the CD8 molecule.
[0471] Briefly, female CB17.SCID.bg mice were inoculated subcutaneously in the right flank with 10 million TALL1 cells in a 50:50 mixture of HBSS:Matrigel. Once tumors reached approximately 400 m3 in size, animals were separated for PET imaging. 89 For imaging with Zr-OA-anti-CD8 antibody, animals were injected via the tail vein and underwent static PET scans on days 0, 1, 2, and 5. For imaging with 18F-anti-CD8 VHH, animals were injected via the tail vein and underwent dynamic 60-min PET scans as before.
[0472] Region of interest (ROI) measurements were performed on multiple axial sections of tissue using IRW software (Siemens Preclinical Solutions, Inc.) The decay-corrected signal intensity of the organ was measured as a percentage of injected dose per gram (%ID / g), assuming 1 cc equivalent in 1 gram of soft tissue.
[0473] 18 F-anti-CD8 VHH allows rapid visualization of low CD8-expressing TALL1 xenograft tumors within 1 hour. Fig.10 As shown in , TALL1 xenograft tumors expressing CD8 could be clearly visualized 90 minutes after injection, and a high tumor-to-blood ratio of 14 was achieved. 18 F-anti-CD8 VHH imaging can be completed in 0.5 - 4 hours. 89 Zr-OA-anti-CD8 antibody is suitable for meaningful imaging at longer time points, i.e., 1 to 5 days after injection. Due to its small size, 18 F-anti-CD8 VHH penetrates tissue very rapidly and exhibits rapid renal clearance, facilitating the performance of additional PET scans (e.g., FDG PET) on the same patient later in the same day, or repeat PET scans as early as the next day. 18 F mark (or other mark, such as 68 The compatibility of Ga) provides imaging procedures with anti-CD8 VHHs that result in a relatively low radiation burden to the patient, so additional scans can be performed throughout the course of treatment within common dosimetry guidelines for human patients. 18 F-anti-CD8 VHH, the same patient may be re-imaged up to approximately 5 times during the typical months or years of long treatment and follow-up.
[0474] PET imaging studies in rhesus monkeys
[0475] In rhesus monkeys18 F-anti-CD8 VHH imaging experiments were performed to determine whether uptake could be detected in tissues that are normally rich in CD8. Rhesus monkeys (2.5 kg) were injected with 64 μg of 18 F- Anti-CD8 VHH. CD8-rich tissues, such as lymph nodes, thymus, and spleen, can be clearly imaged within 1 hour after injection. Fig.11 The top image shows a PET MIP image one hour after injection. 18 F- One hour after control VHH, no CD8-rich tissue was seen in the PET MIP images ( Fig.11 Bottom). Only clearance to the kidneys was significant.
[0476] Example 3: Use of CD8 Imaging to Determine the Effect of Immunotherapy on Cancer, Autoimmune Disease or Condition, Transplant Methods for the efficacy of rejection or graft-versus-host disease
[0477] The CD8 binding agents described herein, for example 18 F-anti-CD8 VHH, for evaluation of CD8 + Infiltration of tumors and lymph nodes by cells. This type of imaging is used to identify immune phenotypes that may predict patient prognosis and / or response to immunotherapy. For example, this type of imaging is used to determine the presence of CD8 + The prevalence of T-cells. This imaging is useful for selecting immunotherapeutic agents or combination therapies including one or more immunotherapeutic agents for patients with cancer, autoimmune diseases or conditions (e.g., arthritis, colitis, or celiac disease), transplant rejection, or graft-versus-host disease.
[0478] In all embodiments disclosed herein, immunotherapy for cancer patients is, for example, any anti-PD1 agent or anti-PDL1 agent disclosed herein, such as monoclonal antibodies for treating cancer, bispecific antibodies that bind T cells and tumor-associated proteins, bispecific antibodies that bind NK cells and tumor-associated proteins, cytokines, CAR-T cell therapy, non-specific cancer immunotherapy and adjuvants, and immune checkpoint inhibitors. Bispecific antibodies that bind T cells and tumor-associated proteins include, for example, anti-CD3 bispecific antibodies. Bispecific antibodies that bind NK cells and tumor-associated proteins include, for example, anti-CD16 (FcγRIII) bispecific antibodies, anti-CD16A bispecific antibodies, anti-CD56 bispecific antibodies, anti-NKp46 bispecific antibodies, and any other NK-cell binding bispecific antibodies.
[0479] In some embodiments, a CD8 binding agent (e.g., 18F-anti-CD8 VHH) can be used for the treatment, diagnosis, prognosis, companion diagnostic and monitoring progression / remission of diseases as described herein, such as cancer, autoimmune diseases or conditions, transplant rejection or graft-versus-host disease.
[0480] In some embodiments, a CD8 binding agent (e.g., 18 F-anti-CD8 VHH) can be used to image subjects who have failed treatment with an immunotherapeutic agent for a disease (e.g., cancer, an autoimmune disease or condition, transplant rejection, or graft-versus-host disease), where the imaging results explain one or more mechanisms of treatment failure. For example, a subject may receive an atezolizumab combination but not respond to treatment. The imaging results may reveal that the subject has lost CD8+ tumor cells, or still has CD8+ tumor cells, but the therapeutic has been exhausted or is no longer effective against the CD8+ tumor cells.
[0481] Example 4: Methods for microbiome research and immune phenotype identification using CD8 imaging
[0482] The CD8 binding agents described herein, for example 18 F - Anti-CD8 VHH, can be used to evaluate CD8 + This imaging is used to identify immune phenotypes that underlie microbiome signatures that predict patient prognosis and / or response to cancer immunotherapy.
[0483] In addition, the CD8 binding agents described herein, such as 18 F-anti-CD8 VHH, can be used to identify CD8 + Microbiome signatures that correlate with specific systemic patterns in T-cell biodistribution. For example, this imaging is used to determine the presence of CD8 + The prevalence of T-cells. This imaging is used to select the most robust microbiome biomarkers, even when direct associations with outcomes are confounding or weak.
[0484] Colonizing gut bacteria may influence patient response to cancer immunotherapy. See, e.g., Gopalakrishnan et al., (2018) Science. 359(6371): 97-103. Therefore, identifying key microbial strains associated with patient responsiveness to cancer immunotherapy may be useful for identifying appropriate treatment options for cancer patients. The CD8 binding agents described herein, e.g. 18 F-anti-CD8 VHH, can be used to identify one or more microbiome profiles (e.g., one or more gut flora compositions) that are associated with a patient's responsiveness to an immunotherapy (e.g., the immunotherapy discussed herein).
[0485] Briefly, a gut microbiome sample (e.g., a stool sample) is obtained from a cancer patient who is to undergo immunotherapy (e.g., an immunotherapy described elsewhere herein). Prior to each patient undergoing cancer immunotherapy, a CD8 binding agent described herein, e.g., 18 F-anti-CD8 VHH, administered to them, and CD8 was assessed in each patient + The patients were then each treated with a cancer immunotherapy (e.g., an immunotherapy described herein). The CD8 binding agents described herein, e.g., 18 F- anti-CD8 VHH, re-administered to patients after cancer immunotherapy, and CD8 was assessed a second time in each patient + Infiltration of tumors and lymph nodes by CD8 T cells. The level of CD8 T cells infiltration in one or more tumors and lymph nodes of patients after immunotherapy was assessed, and the microbiome profile of each patient was determined (e.g., the types of microorganisms present in the gut microbiome sample, and the abundance of each type of microorganism). + Key microbial strains present in gut microbiome samples from patients with infiltration of T cells into one or more tumors and lymph nodes.
[0486] In the presence of CD8 + After identifying key microbial strains in patients with T cell infiltration into lymph nodes and / or tumors, microbiome drugs containing key microbial strains were prepared from donor feces obtained from these patients. + T cells into lymph nodes or tumors. + Stool collected from donors with T cell infiltration into lymph nodes and / or tumors was not used for patients who did not show CD8 + Patients with infiltration of T cells into lymph nodes and / or tumors undergo FMT (fecal microbiota transplant) procedures. In some embodiments, FMT or microbiome drugs can be used to treat cancer cells that do not express CD8 T cells after cancer immunotherapy. + The study also found that patients with infiltration of the lymph nodes and / or tumors were converted to those who responded to cancer immunotherapy.
[0487] In some embodiments, the patient does not express CD8 + Patients with infiltration of lymph nodes and / or tumors were imaged for CD8. After FMT or microbiome drug administration, patients received immunotherapy. After immunotherapy, patients were imaged to determine whether FMT or microbiome drug resulted in increased CD8 +In some embodiments, if increased CD8 + If infiltration is detected, FMT or other microbiome therapy is considered successful.
[0488] The CD8 imaging agents used in conjunction with microbiome research and discovery can be any of the CD8 binding agents described herein, e.g. 18 F—anti-CD8 VHH, wt2C8 VHH, 2C8v130 VHH, 2C8v142 VHH or 2C8v144 VHH were used.
[0489] In some embodiments, the cancer immunotherapy is a checkpoint inhibitor. In some embodiments, the cancer immunotherapy is a T-cell targeted therapy. In some embodiments, the T-cell targeted therapy is a T-cell bispecific, trispecific, or multispecific antibody or antigen-binding fragment thereof. In some embodiments, the cancer immunotherapy is a NK cell targeted therapy. In some embodiments, the NK cell targeted therapy is a bispecific, trispecific, or multispecific antibody or antigen-binding fragment thereof.
[0490] In some embodiments, a CD8 binding agent described herein (e.g. 18 CD8 imaging using F-anti-CD8 VHH) can be used to assess tumor and lymph node CD8 before, during, and after administration of checkpoint inhibitors or immunomodulatory molecules such as CD16 or CD3 targeting moieties. + This imaging is used to determine microbiome biomarkers that correlate with the efficacy of checkpoint inhibitors or immune modulatory molecules such as CD16 or CD3 targeting moieties.
[0491] The checkpoint inhibitor used in the examples can be any checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is an anti-PD1 or anti-PDL1 antibody. In some embodiments, the checkpoint inhibitor is atezolizumab (TECENTRIQ ® ).
[0492] The immunomodulatory molecule can be any molecule that affects the proliferation and infiltration of CD8 cells. Examples include T-cell bispecific molecules, such as antibodies that bind CD3 and tumor-associated antigens and molecules that bind CD16 and tumor-associated antigens.
[0493] The exemplary embodiments and examples are provided for the purpose of illustration only and are not intended to limit the scope of the present application in any way. In fact, various modifications other than those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.
Claims
1. A CD8 binding agent comprising a variable domain of a heavy chain of a heavy chain antibody (VHH domain), wherein the VHH domain comprises: (1) a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 8, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 10; (2) a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 11; (3) a CDR1 consisting of the amino acid sequence of SEQ ID NO: 7, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 11; or (4) CDR1 consisting of the amino acid sequence of SEQ ID NO: 6, CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 12; and wherein the CD8 binding agent has a K of 0.15 nM or less D Binds specifically to human CD8.
2. The CD8 binding agent of claim 1, wherein the VHH domain comprises a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and a CDR3 consisting of the amino acid sequence of SEQ ID NO:
12.
3. The CD8 binding agent of claim 1 or claim 2, wherein (a) the VHH domain comprises a L49A substitution, wherein the amino acid modification is introduced into the framework region as shown in SEQ ID NO: 1, and wherein the numbering is according to Kabat numbering; and / or (b) the VHH domain comprises amino acid modifications consisting of a V89T substitution, a T110Q substitution, a S112Q substitution and an A114 addition, wherein the amino acid modifications are introduced into the framework regions as shown in SEQ ID NO: 1, and wherein the numbering is according to Kabat numbering; and / or (c) The CD8 binding agent does not comprise an Fc region.
4. The CD8 binding agent of any one of claims 1-3, wherein the VHH domain comprises the amino acid sequence of any one of SEQ ID NOs: 1-4.
5. An isolated nucleic acid encoding the CD8 binding agent of any one of claims 1-4.
6. An expression vector comprising the nucleic acid of claim 5.
7. A host cell comprising the nucleic acid of claim 5 or the expression vector of claim 6.
8. The host cell of claim 7, wherein the host cell is a eukaryotic cell or a prokaryotic cell.
9. The host cell of claim 8, wherein the eukaryotic cell is a mammalian cell.
10. The host cell of claim 9, wherein the mammalian cell is an Expi293 cell.
11. A method for preparing a CD8 binding agent, the method comprising: a) culturing the host cell of any one of claims 7 to 10 under conditions wherein the agent is produced; and b) recovering the CD8 binding agent produced by the host cells.
12. The CD8 binding agent of any one of claims 1-4, wherein the VHH domain is conjugated to a label.
13. The CD8 binding agent of claim 12, wherein the label is a fluorescent dye, a radionuclide or an enzyme.
14. The CD8 binding agent of claim 13, wherein the radionuclide is 18 F. 32 P. 33 P. 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Sc, 77 As, 86 Y. 89 Sr. 89 Zr, 90 Y. 90 Nb, 94 Tc, 99 Tc, 99 mTc, 99 Mo, 105 Pd, 105 Rh, 111 Ag, 111 In, 123 I. 124 I. 125 I. 131 I. 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 169 2. 175 Lu, 177 Lu, 186 Re, 188 Re, 189 Re, 194 Ir, 198 Au, 199 Au, 211 At 211 Pb, 212 Bi, 212 Pb, 213 Bi, 223 Ra or 225 Ac.
15. The CD8 binding agent of claim 14, wherein the radionuclide is 18 F. 89 Zr, 99m Tc, 67 Ga, 68 Ga, 64 Cu, 52 Mn, 111 In or 124 I.
16. The CD8 binding agent of claim 15, wherein the radionuclide is 18 F.
17. The CD8 binding agent of any one of claims 12-16, wherein the VHH domain is conjugated to a label via a chelating moiety.
18. The CD8 binding agent of claim 17, wherein the chelating moiety is covalently linked to the VHH domain via a lysine residue.
19. The CD8 binding agent of claim 17 or 18, wherein the label forms a complex with a metal, wherein the complex is chelated by a chelating moiety.
20. The CD8 binding agent of claim 19, wherein the marker is 18 F and the metal is aluminum.
21. The CD8 binding agent of claim 20, wherein the chelating moiety is a compound of formula (I):
22. The CD8 binding agent of any one of claims 1-4 or 12-21, comprising a compound of formula (I) and [ 18 F]-aluminum fluoride complex conjugated VHH domain, wherein the VHH domain comprises a CDR1 consisting of the amino acid sequence of SEQ ID NO: 6, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and a CDR3 consisting of the amino acid sequence of SEQ ID NO:
12.
23. The CD8 binding agent of claim 22, wherein the VHH domain comprises the amino acid sequence of SEQ ID NO: 4 and the CD8 binding agent does not comprise an Fc region.
24. A pharmaceutical composition comprising the CD8 binding agent of any one of claims 1-4 and 12-23.
25. A pharmaceutical composition according to claim 24, comprising (i) a pharmaceutically acceptable excipient; and / or (ii) one or more antioxidant compounds.
26. A kit comprising the CD8 binding agent of any one of claims 1-4 and 12-23 or the pharmaceutical composition of claim 24 or 25.
27. The kit according to claim 26, further comprising reagents for preparing a labeled CD8 binding agent.
28. The kit according to claim 27, wherein the reagents used to prepare the labeled CD8 binding agent are a chelating agent of formula (I) and [ 18 F]-aluminum fluoride complex.
29. The labeled CD8 binding agent of any one of claims 12 to 23 or the pharmaceutical composition of claim 24 or 25 for use in a method of treatment, diagnosis, prognosis, therapy selection or and monitoring response to therapy.
30. A labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25 for use according to claim 29, wherein monitoring response to therapy comprises monitoring progression / remission of the disease.
31. A labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25 for use according to claim 30, wherein the disease is cancer, an autoimmune disease or condition, transplant rejection or graft versus host disease.
32. The labeled CD8 binding agent of any one of claims 12 to 23 or the pharmaceutical composition of claim 24 or 25 for use in detecting CD8 in a subject. + In a method for producing a cell, the method comprises: a) administering to the subject a labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25; and b) detecting the binding of the labeled CD8 binding agent to the CD8 in the subject + cells, wherein detection of said binding indicates the presence of CD8 + cell.
33. A labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25 for use according to claim 32, wherein (i) detecting the binding of the labeled CD8 binding agent to the CD8 in the subject + The binding of cells includes CD8 + The cells are imaged; and / or (ii) to CD8 + Imaging the cells may include performing a positron emission tomography (PET) scan or a positron emission tomography / computed tomography (PET / CT) scan of the subject.
34. A labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25 for use according to claim 32 or 33, wherein the subject is a human or non-human mammal.
35. A labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25 for use according to claim 34, wherein the subject is a human.
36. A labeled CD8 binding agent according to any one of claims 12 to 23 or a pharmaceutical composition according to claim 24 or 25 for use according to claim 34, wherein the non-human mammal is a rat, mouse, guinea pig, hamster, rabbit, dog, cat, cow, horse, goat, sheep, donkey, pig, monkey or ape.
37. A method for preparing a labeled CD8 binding agent, comprising conjugating a chelating moiety to the VHH domain of the CD8 binding agent of any one of claims 1 to 4 to provide a conjugate, and mixing the conjugate with a 18 F to provide a labeled CD8 binding agent, wherein the chelating moiety is a compound of formula (I):
